Methods for cardiovascular disease in rheumatoid arthritis

The VECTRA-CVD score, combining biomarkers and clinical parameters, addresses the inaccuracy of conventional CVD risk assessment in RA patients by providing a precise and timely method to identify and treat CVD risk, considering systemic inflammation.

JP2024161429APending Publication Date: 2024-11-19CRESCENDO BIOSCI +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024130864
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-11-01
Filing Date
2024-08-07
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Conventional methods for assessing cardiovascular disease (CVD) risk in patients with inflammatory diseases like rheumatoid arthritis (RA) are inaccurate and do not adequately consider the impact of systemic inflammation, often underestimating the increased risk and failing to provide real-time point-of-care solutions.

Method used

A method utilizing biomarkers such as VECTRA-CVD score, combined with clinical parameters, to predict CVD risk in RA patients by determining the levels of biomarkers like leptin, TNFRI, and MMP3, and adjusting with additional clinical variables to generate an accurate 3-year risk score.

Benefits of technology

Provides a surprisingly accurate and efficient method for predicting CVD risk in RA patients, reflecting systemic inflammation and enabling real-time risk assessment and treatment recommendations, expanding the population of patients eligible for treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161429000001_ABST
    Figure 2024161429000001_ABST
Patent Text Reader

Abstract

To provide methods for assessing and treating risk of cardiovascular disease (CVD) in a subject with an inflammatory disease, for example, rheumatoid arthritis (RA), the methods for assessing risk, for recommending therapy, for prognosis and monitoring, and for treatment, which are advantageously accurate for CVD in RA.SOLUTION: The methods include the steps of: measuring quantitative data for biomarkers; calculating a CVD risk score for a subject using training data; and validating the CVD risk score with a set of validation clinical data.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the fields of medicine and bioinformatics. More specifically, the present invention relates to a method for evaluating and treating inflammatory and autoimmune diseases and associated cardiovascular diseases. A method for evaluating the risk of cardiovascular disease in patients with inflammatory diseases such as rheumatoid arthritis is disclosed. [Background technology]

[0002] background Rheumatoid arthritis (RA) is an inflammatory disease and chronic systemic autoimmune disorder that affects millions of people worldwide. In RA, the immune system targets the affected joints as well as other organs such as the lungs, blood vessels, and pericardium, resulting in joint inflammation, i.e. arthritis, widespread endothelial inflammation, and destruction of joint tissue.

[0003] There is an association between RA and cardiovascular disease (CVD), including myocardial infarction (MI), heart failure and stroke. It is estimated that nearly half of RA-related deaths are the result of CVD and its underlying atherosclerosis, itself an inflammatory disorder. Pathogenic features common to both RA and atherosclerosis include elevated levels of proinflammatory cytokines, acute phase reactants, angiogenesis, T-cell activation, and leukocyte adhesion molecules, as well as endothelial cell injury.

[0004] Compared with the general population, RA patients are at higher risk of CVD. The drawback of conventional methods for assessing CVD risk in RA is that they often only explain a small portion of the increased CVD risk in RA. Some conventional methods underestimate CVD risk in RA patients because they do not take into account the effects of RA and its characteristics, including inflammation.

[0005] Furthermore, most conventional methods for CVD risk prediction do not include RA as an independent risk factor. Some conventional methods, such as the Renolyds risk score, quantify systemic inflammation and include C-reactive protein (CRP) as a component, but the generalizability, accuracy, and utility of this biomarker for CVD risk prediction in RA patients are unclear.

[0006] Another drawback of conventional methods, such as the ACC / AHA pooled cohort risk calculator for the general population without RA, is that few are available in real time to clinicians at the point of care where they may be most informative: the method has been shown to have accuracy deficiencies in several population-based cohorts.

[0007] Therefore, risk assessment and stratification using CVD risk prediction is useful to characterize risk and the need for intervention and treatment in patients and the general population.

[0008] What is needed is an efficient and accurate method for predicting CVD event risk in RA patients that reflects systemic inflammation and other factors. A conveniently accessible risk stratification method could facilitate the treatment of RA patients.

[0009] There is an urgent need for methods to assess systemic inflammation through the use of biomarkers and other factors that reflect RA disease activity and complexity, including associated CVD risk. Methods that can be efficiently implemented at the point of care for RA are needed. Summary of the Invention

[0010] overview The present invention provides methods for assessing cardiovascular disease (CVD) risk. In some aspects, the present invention utilizes biomarkers associated with inflammatory diseases that can be used in methods for assessing and treating inflammatory and autoimmune diseases, and associated cardiovascular diseases.

[0011] In some aspects, the present invention provides a method for assessing the risk of cardiovascular disease in patients with inflammatory disease. Inflammatory disease may have an associated risk of cardiovascular disease. The method of the present invention can be used to assess and treat cardiovascular disease associated with rheumatoid arthritis.

[0012] The present invention can provide an efficient and accurate method for predicting CVD event risk in RA patients.The method of the present disclosure can reflect the impact of systemic inflammation in RA as well as other patient-related factors.The present invention can provide a surprisingly accurate method for predicting CVD risk in RA patients.

[0013] Further aspects of the present disclosure provide methods for assessing systemic inflammation through the use of biomarkers and other factors that reflect RA disease activity and complexity, including associated CVD risk.

[0014] The method disclosed herein can be effectively implemented in RA point of care, and can expand the patient population that is included in treatment.In some embodiments, the present invention includes the surprisingly improved accuracy of assessing CVD risk in RA, which allows patients to be reclassified as having higher risk than expected.These patients who would not have been treated otherwise can be treated.

[0015] The present invention is directed to assess the risk of CVD in a subject with inflammatory disease by determining the subject's CVD 3-year risk score. The subject can be a patient aged 40 years or older who has no history of heart attack or stroke. The CVD 3-year risk score can be determined by obtaining a VECTRA-CVD score, and the VECTRA-CVD score can be associated with the subject's RA disease activity that is algorithmically combined with various clinical parameters of the subject. The RA disease activity in a subject can be determined using an adjusted VECTRA score that combines the values ​​obtained for various biomarkers that are algorithmically combined with various clinical parameters of the subject.

[0016] The 3-year risk score for CVD can be used to assess the risk of CVD in subjects with an inflammatory disease such as RA.

[0017] The CVD 3-year risk score can be used to provide efficient and surprisingly accurate prediction and prognosis of CVD event risk in RA patients. The CVD 3-year risk score of the present disclosure can reflect the impact of systemic inflammation in RA.

[0018] The VECTRA-CVD score can be determined based on the adjusted VECTRA score, which can be algorithmically combined with the subject's clinical parameters, and additional adjustments for each of the leptin, TNFRI, and MMP3 biomarkers. The relevant clinical parameters of the subject can be age, smoking status, presence of diabetes, presence of hypertension, and history of CVD.

[0019] An adjusted VECTRA score can be determined based on an MBDA score that utilizes several VECTRA biomarkers, along with clinical variables of the subject's age and sex, and another adjusted condition-based value for the leptin biomarker.

[0020] In some aspects, the VECTRA marker can be selected from chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1); C-reactive protein, pentraxin-related (CRP); epidermal growth factor (beta urogastron) (EGF); interleukin 6 (interferon, beta 2) (IL6); leptin (LEP); matrix metallopeptidase 1 (interstitial collagenase) (MMP1); matrix metallopeptidase 3 (stromelysin 1, progelatinase) (MMP3); resistin (RETN); serum amyloid A1 (SAA1); tumor necrosis factor receptor superfamily, member 1A (TNFRSF1A); vascular cell adhesion molecule 1 (VCAM1); and vascular endothelial growth factor A (VEGFA).

[0021] In a further aspect, the present disclosure describes a method for assessing the risk of CVD in a subject with inflammatory disease, which may be RA.The method includes: assaying a sample obtained from a subject to detect the level of at least two VECTRA markers, and using an interpretation function to calculate the CVD risk score of the subject from biomarker levels and clinical values.The CVD risk score can be a CVD 3-year risk score.

[0022] In a further aspect, the present disclosure describes a method for recommending treatment for a subject with inflammatory disease, which may be RA and may be at risk for cardiovascular disease (CVD).The method includes: assaying a sample obtained from the subject to detect the levels of at least two VECTRA markers; and calculating the subject's CVD risk score from the biomarker levels and clinical values ​​using an interpretation function.The method may include recommending treatment for CVD based on a CVD risk score that is above a threshold level, or recommending no treatment for CVD based on a CVD risk score that is below a threshold level.The CVD risk score may be a CVD 3-year risk score.

[0023] In a further aspect, the present disclosure describes a method for identifying subjects with inflammatory disease and at risk of cardiovascular disease (CVD), who will benefit from treatment.The method includes: assaying a sample obtained from a subject to detect the levels of at least two VECTRA markers; and calculating the subject's CVD risk score from the biomarker levels and clinical values ​​using an interpretation function.The method can include identifying subjects with inflammatory disease and at risk of cardiovascular disease (CVD), who will benefit from treatment of CVD, based on a CVD risk score that exceeds a threshold level.The CVD risk score can be a CVD 3-year risk score.

[0024] In a further aspect, the present disclosure describes a method for treating CVD in a subject having inflammatory disease and in need of CVD treatment. The method includes: assaying a sample obtained from the subject to detect the level of at least two VECTRA markers; and calculating the subject's CVD risk score from the biomarker level and clinical value using an interpretation function. The method can include identifying a subject with inflammatory disease and cardiovascular disease (CVD) risk based on a CVD risk score that exceeds a threshold level; and administering CVD and / or RA treatment to the subject. The method can include monitoring the subject for CVD signs and symptoms for a period of time before administering CVD and / or RA treatment to the subject. The CVD risk score can be a CVD 3-year risk score.

[0025] In a further aspect, the present disclosure describes a method for monitoring the response of a subject with inflammatory disease and at risk of CVD to treatment.The method includes: assaying a sample obtained from the subject to detect the level of at least two VECTRA markers; and calculating the subject's CVD risk score from the biomarker level and clinical value using an interpretation function.The method can include identifying a subject with inflammatory disease and at risk of cardiovascular disease (CVD) based on a CVD risk score that exceeds a threshold level.The CVD risk score can be a CVD 3-year risk score.

[0026] In a further aspect, the present disclosure describes a method for prognosing a subject with inflammatory disease and at risk of having CVD.The method includes: assaying a sample obtained from the subject to detect the levels of at least two VECTRA markers; and calculating the subject's CVD risk score from the biomarker levels and clinical values ​​using an interpretation function.The method can include prognosing the subject as having a poor prognosis for CVD based on the CVD risk score exceeding a threshold level.The CVD risk score can be a CVD 3-year risk score.

[0027] Embodiments of the invention include kits for assessing the risk of cardiovascular disease (CVD) in a subject with an inflammatory disease, the kit comprising reagents for measuring for two or more VECTRA biomarkers in a sample from a subject, and instructions for using the reagents to obtain biomarker levels.

[0028] The present invention encompasses a system for assessing risk of cardiovascular disease (CVD) in a subject having an inflammatory disease, the system comprising one or more processors together with a display for performing the steps of calculating a subject's CVD risk score using an interpretation function from biomarker protein levels and one or more clinical conditions, and identifying a subject having an inflammatory disease and at risk of cardiovascular disease (CVD) based on a CVD risk score exceeding a threshold level.

[0029] The invention further encompasses a non-transitory machine-readable storage medium having stored therein instructions for execution by a processor, the instructions causing the processor to perform the steps of a method for assessing risk of cardiovascular disease (CVD) in a subject having inflammatory disease, the method including receiving measured protein levels for two or more VECTRA biomarkers in a sample from the subject, calculating a subject's CVD risk score from the biomarker protein levels and one or more clinical conditions using an interpretation function, identifying a subject having inflammatory disease and at risk for cardiovascular disease (CVD) based on a CVD risk score exceeding a threshold level, and transmitting the CVD risk score to a processor output for display and / or reporting.

[0030] In some embodiments of each of the above aspects, the at least two markers may include two or more of: CHI3L1; CRP; EGF; IL6; LEP; MMP1; MMP3; RETN; SAA1; TNFR1; VCAM1; and VEGFA.

[0031] In some embodiments, the test score can be compared with a clinical assessment. In some embodiments, the clinical assessment can be selected from the group consisting of DAS, DAS28, DAS28-CRP, DAS28-ESR, Sharp score, tender joint count (TJC), and swollen joint count (SJC). In some embodiments, the assay can include carrying out a multiplex assay.

[0032] In some embodiments, an assay may include obtaining a sample containing a protein marker; contacting the sample with a plurality of different reagents; generating a plurality of different complexes between the reagents and the marker; and detecting the complexes to detect a level.

[0033] The sample in the method of the present invention may be a blood sample.

[0034] In a further embodiment, the at least one clinical variable can be selected from age, gender, sex, smoking status, obesity, body mass index (BMI), serum leptin and race / ethnicity. The clinical variable can be one or more of age, sex, and race. The clinical variable can be one or more of age and sex.

[0035] In some embodiments, the first treatment regimen can be selected from the treatment regimen administered to the subject at the time the sample is obtained; the cessation of the treatment regimen administered to the subject at the time the sample is obtained; the tapering of the treatment regimen administered to the subject at the time the sample is obtained; or no treatment regimen.In further embodiments, the second treatment regimen can be selected from statin drugs, dietary modification, and EKG.

[0036] Aspects of the invention include the following.

[0037] A method for assessing risk of cardiovascular disease (CVD) in a subject having an inflammatory disease, comprising the steps of: detecting in a sample from the subject leptin (LEP), tumor necrosis factor receptor superfamily, member 1A (TNFR1), matrix metallopeptidase 3 (stromelysin 1, progelatinase) (MMP3), C-reactive protein, pentraxin-related (CRP), interleukin 6 (interferon, beta 2) (IL6), serum amyloid A1 (SAA1), chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1), epidermal growth factor (beta-urogastron) (EGF), vascular cell adhesion molecule 1 (VCAM1), matrix metallopeptidase 3 (MT3) (IL3), and / or IL6-dependent inflammatory responses. Measuring protein levels for three or more biomarkers from a biomarker set including putidase 1 (interstitial collagenase) (MMP1), resistin (RETN), and vascular endothelial growth factor A (VEGFA); calculating a subject's CVD risk score using an interpretation function using the protein levels, one or more clinical conditions, and a set of training clinical data from a reference group, wherein the three or more biomarkers include LEP, TNFR1, and MMP3; and validating the CVD risk score using the interpretation function using the protein levels, one or more clinical conditions, and a set of validation clinical data from the reference group.

[0038] The sample may be a blood sample. The subject may be over 40 years old. The subject may not have a history of heart attack or stroke. The inflammatory disease may be rheumatoid arthritis (RA). The clinical conditions may include age, sex, smoking, diabetes, hypertension, and history of cardiovascular disease, or age, sex, smoking, diabetes, hypertension, history of cardiovascular disease, gender, obesity, body mass index, race, and ethnicity.

[0039] The reference group may be patients tested for rheumatoid arthritis (RA) and / or cardiovascular disease (CVD) activity. The reference group may be Medicare patients.

[0040] The three or more biomarkers may include LEP, TNFR1, MMP3, CRP, IL6, and SAA1. The three or more biomarkers may include LEP, TNFR1, MMP3, CRP, IL6, SAA1, CHI3L1, EGF, VCAM1, MMP1, RETN, and VEGFA.

[0041] The CVD risk score can be validated using clinical data selected from the DAS score, the DAS28 score, the DAS28-CRP score, the DAS28-ESR score, the Sharp score, the tender joint count score (TJC), and the swollen joint count score (SJC).

[0042] The step of calculating the CVD risk score may include calculating an adjusted MBDA score and calculating the CVD risk score by combining the adjusted MBDA score with clinical conditions using an interpretation function.

[0043] Interpretation functions include survival regression analysis, Cox proportional hazards, Box-Cox transformation, clustering machine learning, hierarchical clustering analysis, centroid clustering, distributional clustering, density clustering, cluster data mining, analysis of variance (ANOVA), AdaBoosting, classification and regression trees (CART), boosted CART, random forests (RF), recursive partitioning trees (RPART), Curds and Whey (CW), Curds and Whey-Lasso, principal component analysis (PCA), factor rotation analysis, linear discriminant analysis (LDA), Eigengene linear discriminant analysis (ELDA), quadratic discriminant analysis, discriminant function analysis (DFA), hidden Markov models, kernel density estimation, kernel partial least squares algorithm, kernel matching pursuit algorithm, kernel Fisher discriminant analysis algorithm, kernel principal component analysis algorithm; linear regression, stepwise regression, incremental stepwise regression, Lasso shrinkage selection method, Elastic Net regularization and selection, Lasso and Elastic The interpretation function may include one or more of: Net regularized generalized linear model, logistic regression (LogReg), K nearest neighbors (KNN), nonlinear regression, classification, neural networks, partial least squares, rule-based classification, shrunken centroids (SC), sliced ​​inverse regression, Standard for the Exchange of Product model data, Application Interpreted Constructs (StepAIC), super principal component (SPC) regression, support vector machine (SVM), and recursive support vector machine (RSVM), and combinations thereof. The interpretation function may provide an algorithm that includes the hyperbolic tangent or exponential function of the biomarker score.

[0044] The method may include recommending a treatment for CVD to the subject based on a CVD risk score that exceeds a threshold level, or recommending no treatment for CVD based on a CVD risk score that is less than a threshold level. The treatment may be one of the following: the treatment administered to the subject at the time the sample is obtained; the cessation of the treatment administered to the subject at the time the sample is obtained; the tapering of the treatment administered to the subject at the time the sample is obtained. The treatment may be one or more of administering a drug, performing surgery, performing rehabilitation, administering treatment for another disease or condition of the subject, and improving the symptoms of the subject. The treatment may be administering one or more drugs selected from cholesterol-lowering drugs, blood flow-increasing drugs, cardiac rhythm regulators, cardiac rhythm stabilizers, drugs that reduce blood blockage, beta-blockers, ACE inhibitors, aldosterone inhibitors, angiotensin II receptor blockers, calcium channel blockers, cholesterol-lowering drugs, diuretics, inotropes, electrolyte supplements, PCSK9 inhibitors, and vasodilators. The treatment may be administering a DMARD selected from MTX, azathioprine (AZA), bucillamine (BUC), chloroquine (CQ), cyclosporine, doxycycline (DOXY), hydroxychloroquine (HCQ), intramuscular gold (IM gold), leflunomide (LEF), levofloxacin (LEV), sulfasalazine (SSZ), folinic acid, D-pencilamine, gold auranofin, gold aurothioglucose, gold thiomalate, cyclophosphamide, chlorambucil, infliximab, adalimumab, etanercept, golimumab, anakinra, abatacept, rituximab, and tocilizumab. The treatment may be one or more of percutaneous coronary intervention, coronary artery bypass surgery, heart valve repair or replacement surgery, bariatric surgery, cardiac rehabilitation, therapeutic physical programs, dietary modification or restriction, smoking cessation, diabetes treatment, hypertension treatment, symptom relief, reducing the risk of recurrence, reducing the severity of recurrence, reducing heart failure or heart attack, and reducing stroke.

[0045] The method can include identifying a subject having an inflammatory disease and at risk for cardiovascular disease (CVD) that would benefit from treatment for CVD based on a CVD risk score exceeding a threshold level. The threshold level can be one of a borderline risk threshold, a medium risk threshold, and a high risk threshold based on a CVD 3-year risk or a CVD 10-year risk.

[0046]

[0013] Aspects of the invention further contemplate a method for treating cardiovascular disease (CVD) in a subject having an inflammatory disease and in need of treatment for CVD, the method comprising detecting in a sample from the subject leptin (LEP), tumor necrosis factor receptor superfamily, member 1A (TNFR1), matrix metallopeptidase 3 (stromelysin 1, progelatinase) (MMP3), C-reactive protein, pentraxin related (CRP), interleukin 6 (interferon, beta 2) (IL6), serum amyloid A1 (SAA1), chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1), epidermal growth factor (beta-urogastrone) (EGF), vascular cell adhesion molecule 1 (VCAM1), matrix metallopeptidase 1 (interstitial collagenase) (MMP1), resistin (RE), or a combination of these. measuring protein levels for three or more biomarkers from a biomarker set including LEP, TNFR1, and vascular endothelial growth factor A (VEGFA); calculating a CVD risk score for the subject using an interpretation function using the protein levels, one or more clinical conditions, and a set of training clinical data for a reference group, the three or more biomarkers including LEP, TNFR1, and MMP3; validating the CVD risk score using an interpretation function using the protein levels, the one or more clinical conditions, and a set of validation clinical data for the reference group; identifying a subject having an inflammatory disease and at risk for cardiovascular disease (CVD) based on a CVD risk score exceeding a threshold level; and administering a treatment for CVD or RA to the subject.

[0047] The method can include identifying a subject who has an inflammatory disease and is at risk for cardiovascular disease (CVD), and who would benefit from treatment for CVD, based on a CVD risk score that exceeds a threshold level.

[0048] In a further aspect, the invention includes a method for prognosing a subject having an inflammatory disease and at risk of having CVD, the method comprising measuring in a blood sample from the subject leptin (LEP), tumor necrosis factor receptor superfamily, member 1A (TNFR1), matrix metallopeptidase 3 (stromelysin 1, progelatinase) (MMP3), C-reactive protein, pentraxin related (CRP), interleukin 6 (interferon, beta 2) (IL6), serum amyloid A1 (SAA1), chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1), epidermal growth factor (beta-urogastron) (EGF), blood inflammatory disease risk factor (BLD) and / or inflammatory bowel disease risk factor (IGF). The method includes measuring protein levels for three or more biomarkers from a biomarker set including vascular cell adhesion molecule 1 (VCAM1), matrix metallopeptidase 1 (interstitial collagenase) (MMP1), resistin (RETN), and vascular endothelial growth factor A (VEGFA); calculating the subject's CVD risk score using an interpretation function from the protein levels of the biomarkers and one or more clinical conditions, wherein the three or more biomarkers include LEP, TNFR1, and MMP3; and prognosing the subject as having a poor prognosis for CVD based on the CVD risk score exceeding a threshold level.

[0049] Further aspects include a kit for assessing risk of cardiovascular disease (CVD) in a subject having an inflammatory disease, the kit comprising: reagents for measuring, in a blood sample from the subject, protein levels for three or more biomarkers from a set of biomarkers including leptin (LEP), tumor necrosis factor receptor superfamily, member 1A (TNFR1), matrix metallopeptidase 3 (stromelysin 1, progelatinase) (MMP3), C-reactive protein, pentraxin related (CRP), interleukin 6 (interferon, beta 2) (IL6), serum amyloid A1 (SAA1), chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1), epidermal growth factor (beta-urogastron) (EGF), vascular cell adhesion molecule 1 (VCAM1), matrix metallopeptidase 1 (interstitial collagenase) (MMP1), resistin (RETN), and vascular endothelial growth factor A (VEGFA); and instructions for using the reagents to obtain the biomarker levels.

[0050] A further aspect includes a system for assessing risk of cardiovascular disease (CVD) in a subject having an inflammatory disease, the system comprising: leptin (LEP), tumor necrosis factor receptor superfamily, member 1A (TNFR1), matrix metallopeptidase 3 (stromelysin 1, progelatinase) (MMP3), C-reactive protein, pentraxin related (CRP), interleukin 6 (interferon, beta 2) (IL6), serum amyloid A1 (SAA1), chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1), epidermal growth factor (beta-urogastrone) (EGF), vascular cell adhesion molecule 1 (VCAM1), matrix metallopeptidase 1 (interstitial collagenase) (MMP1), resistin ( The method includes receiving a subject's protein levels measured in a blood sample for three or more biomarkers from a set of biomarkers including LEP, TNFR1, and MMP3; one or more processors for performing the following steps: calculating a subject's CVD risk score using an interpretation function from the protein levels of the biomarkers and one or more clinical conditions, wherein the three or more biomarkers include LEP, TNFR1, and MMP3; identifying a subject having an inflammatory disease and at risk for cardiovascular disease (CVD) based on a CVD risk score exceeding a threshold level; and a display for displaying and / or reporting the CVD risk score.

[0051] In a further aspect, the invention includes a non-transitory machine-readable storage medium having stored therein instructions for execution by a processor, the instructions causing the processor to perform steps of a method for assessing risk of cardiovascular disease (CVD) in a subject having an inflammatory disease, the method comprising assessing the ... The method includes receiving measured protein levels from a blood sample from the subject for three or more biomarkers of a biomarker set including interstitial collagenase (ILP), TNFR1, and vascular endothelial growth factor A (VEGFA); calculating a CVD risk score for the subject using an interpretation function from the protein levels of the biomarkers and one or more clinical conditions, the three or more biomarkers including LEP, TNFR1, and MMP3; identifying the subject having an inflammatory disease and at risk for cardiovascular disease (CVD) based on a CVD risk score exceeding a threshold level; and transmitting the CVD risk score to a processor output for display and / or reporting. [Brief description of the drawings]

[0052] [Figure 1] Figure 1 shows the relationship between predicted VECTRA CVD score (x-axis) and CVD 3-year risk % (y-axis) in RA patients. [Diagram 2] The distribution of patients for the relationships in Figure 1 is shown. The distribution in Figure 2 shows that for all levels of the predictive VECTRA CVD score, patients were found with a wide range of CVD 3-year risk %. This distribution and relationship indicates that the score is predictively valid and meaningful for patients at a wide range of risk levels. [Diagram 3] 1 shows the correlation between predicted CVD risk scoring (x-axis) and CVD risk patient outcomes (y-axis). The closeness of the fit of the data points to the dashed line indicates that a very strong correlation exists between the scoring and patient outcomes. [Figure 4] The distribution of patient CVD 3-year risk % against score is shown. [Diagram 5] The results of the method for clinically validating the predictive ability of the CVD 3-year risk % value of the present invention are shown. Figure 5 shows the survival rate of RA subjects without CVD events. The plotted lines show the survival rates corresponding to the low, medium and high CVD risk group thresholds of the predicted CVD 3-year risk % value of the present invention (n=10,275). [Figure 6] The results of the method for clinically validating the predictive ability of the CVD 3-year risk % value of the present invention are shown. Figure 6 shows the survival rate of RA subjects without CVD events. The plotted lines show the survival rates corresponding to the low / borderline, intermediate, and high CVD risk group thresholds of the predicted CVD 3-year risk % value of the present invention (n=10,275). [Figure 7] The results of the method for clinically validating the predictive ability of the CVD 3-year risk % value of the present invention are shown. Figure 7 shows the survival rate of RA subjects free of CVD events. The plotted lines show the survival rates corresponding to the low, borderline, medium and high CVD risk group thresholds of the predicted CVD 3-year risk % value of the present invention (n=10,275). [Figure 8]The present invention shows a superior accuracy of the method in assessing CVD 3-year risk percentage values ​​in RA subjects. The bar graph in FIG. 8 shows that the method of the present invention based on the VECTRA CVD score ("MBDA-based") was surprisingly more accurate than various methods that did not include the VECTRA CVD score. The left bar shows that the determination of CVD risk based only on clinical parameters age and sex was much less accurate than using the VECTRA CVD score. This can be seen by the gradual increase in the likelihood ratio test (LRT) (y-axis, height of the shaded area) from left to right in FIG. 8. Similarly, the second, third and fourth bars from the left also show that the determination of CVD risk based only on the parameters age+sex+CRP (biomarker), a set of clinical parameters that did not include CRP, and a set of clinical parameters that included CRP, respectively, was much less accurate than using the VECTRA CVD score. The sets of clinical parameters were age, sex, diabetes, hypertension, smoking, and CVD history. In summary, FIG. 8 shows that by bivariate analysis, use of the VECTRA CVD score of the present invention may be necessary to achieve very high levels of accuracy in determining CVD 3-year % risk values ​​in RA subjects. [Figure 9]The present invention shows the excellent accuracy of the method in assessing CVD 3-year risk percentage values ​​in RA subjects. The bar graph in FIG. 9 shows that the method of the present invention based on VECTRA CVD score ("MBDA-based") was surprisingly more accurate than various methods that did not include VECTRA CVD score. The left bar shows that the determination of CVD risk based only on the parameters age+gender+CRP (biomarker) was much less accurate than using VECTRA CVD score. This can be seen by the gradual increase in likelihood ratio test (LRT) (y-axis, height of the shaded area) from left to right in FIG. 9. Similarly, the second and third bars from the left also show that the determination of CVD risk based only on the set of clinical parameters that did not include CRP and the set of clinical parameters that included CRP were much less accurate than using VECTRA CVD score, respectively. The set of clinical parameters was age, gender, diabetes, hypertension, smoking, and CVD history. In summary, FIG. 9 shows that by bivariate analysis, use of the VECTRA CVD score of the present invention may be necessary to achieve very high levels of accuracy in determining CVD 3-year % risk values ​​in RA subjects. [Figure 10] The receiver operating curves on day 183 of the models described in Tables 28 to 30 are shown. [Figure 11] The receiver operating curves at day 365 for the models described in Tables 28 to 30 are shown. [Figure 12] The receiver operating curves on day 548 of the models described in Tables 28 to 30 are shown. [Figure 13] The receiver operating curves at day 730 for the models described in Tables 28 to 30 are shown. [Figure 14] The receiver operating curves on day 1095 of the models described in Tables 28 to 30 are shown. [Figure 15] Receiver operating curves on day 183 for the models described in Tables 31 to 33 are shown. [Figure 16] The receiver operating curves at day 365 for the models described in Tables 31 to 33 are shown. [Figure 17]The receiver operating curves on day 548 of the models described in Tables 31 to 33 are shown. [Figure 18] Receiver operating curves at day 730 for the models described in Tables 31 to 33 are shown. [Figure 19] The receiver operating curves on day 1,095 of the models described in Tables 31 to 33 are shown. [Figure 20] The biomarkers used to predict each DAS28-CRP component are shown.

[0053] Those skilled in the art will appreciate that the above drawings are for illustrative purposes and are not intended to limit the scope of the disclosure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0054] Detailed Description of the Disclosure The present invention includes methods for assessing and treating the risk of cardiovascular disease (CVD) in subjects with inflammatory diseases, such as rheumatoid arthritis (RA). Disclosed are risk analysis methods that are advantageously accurate for CVD in RA for the prognosis and treatment of CVD and / or RA.

[0055] The methods of the present invention include performing assays to generate a risk analysis based on quantitative data of the subject's inflammatory disease activity biomarkers and additional clinical variables to further assess and treat CVD risk and / or RA.

[0056] Aspects of the invention further provide bioinformatic methods for determining the risk of cardiovascular disease or myocardial infarction. The risk of cardiovascular disease can be determined not only in the general population, but also for patients with inflammatory diseases such as rheumatoid arthritis.

[0057] The method of the present disclosure can provide CVD risk score based on inflammatory disease activity biomarkers and various clinical variables related to subject.The method can take into account the influence of RA and its characteristics, including inflammation.In such an embodiment, by taking into account the influence of inflammation, provides surprisingly accurate measurement and prognosis of CVD risk in RA patients.

[0058] The present disclosure provides various methods for assessing and treating the risk of CVD in RA. The methods can be used to generate and utilize an adjusted multi-biomarker disease activity score, such as an adjusted MBDA score, in combination with certain clinical variables.

[0059] As used herein, the term "adjusted MBDA score" may refer to an adjusted VECTRA score.

[0060] In some aspects, the present invention can utilize various biomarkers to determine risk of cardiovascular disease.

[0061] In a further aspect, the present invention can utilize various biomarkers that may be associated with subjects having an inflammatory and / or autoimmune disease, such as RA.

[0062] In certain aspects, the present invention can utilize various biomarkers to determine or assess cardiovascular disease (CVD) risk in subjects with inflammatory and / or autoimmune diseases, such as RA.

[0063] In a further aspect, the present invention can utilize various biomarkers to determine CVD risk in RA patients upon response to inflammatory disease treatment and / or CVD treatment.

[0064] In some embodiments, the present disclosure can provide an efficient and accurate algorithm for predicting CVD event risk in RA patients. The algorithm for predicting CVD event risk can take into account the impact of systemic inflammation.

[0065] In a further aspect, the present invention includes an accessible risk stratification algorithm that can facilitate the care of RA patients. The present disclosure includes methods that can be efficiently implemented at the point of care for CVD and / or RA.

[0066] In a further aspect, the present disclosure describes methods of assessing systemic inflammation through the use of biomarkers that reflect RA disease activity.

[0067] In certain embodiments of the invention, an adjusted multi-biomarker disease activity score, such as an adjusted MBDA score, can be used to predict the likelihood or risk of CVD in RA.

[0068] In some aspects, the present disclosure shows that the risk of CVD events in RA may be reduced in patients with lower RA disease activity.Thus, embodiments of the present invention contemplate the management of RA patients by directly intervening in inflammatory pathways to reduce CVD risk.

[0069] In a further aspect, the present invention can be of benefit to RA patients in methods for reducing systemic inflammation via immunological means. In some embodiments, patients with elevated C-reactive protein (CRP) can be treated by directly reducing systemic inflammation to lower the risk of CVD events.

[0070] In a further aspect, the present invention can provide a method for CVD risk stratification in RA, which can be used to identify high-risk patients for medical treatment.CVD risk stratification can include the threshold determined by validation of CVD risk score together with clinical outcome.

[0071] In certain aspects of the invention, the methods for determining CVD risk may be used by clinicians in real time and / or at the point of care.

[0072] In a further aspect, the method of the present invention for assessing CVD risk can be used to consider the effects of RA and its characteristics, including inflammation.By including RA as an independent risk factor, the CVD risk method can accurately estimate the CVD risk of RA patients.

[0073] In a further aspect, the method of the present invention for evaluating and utilizing CVD risk prediction can quantify systemic inflammation and include CRP as an analysis element.In some embodiments, the method of evaluating and utilizing CVD risk prediction can provide surprisingly accurate CVD event risk value in RA patients by including the influence of systemic inflammation.Such method can help make risk stratification more accessible and facilitate the care of RA patients.

[0074] In further embodiments, systemic inflammation can be included in the method for assessing CVD risk of RA by using one or more biomarkers that reflect RA disease activity.In certain embodiments, an adjusted multi-biomarker disease activity score, such as the adjusted MBDA score, can be used to provide results that are highly correlated with RA disease activity measured by, among other scores, the 28-joint disease activity score (DAS28).

[0075] The present invention also contemplates methods and algorithms for CVD risk assessment, which can be useful for clinicians.More specifically, the present invention includes methods for measuring disease markers, and for training and validating algorithms that use markers and clinical variables to assess RA disease activity.

[0076] The disclosed methods and algorithms for assessing CVD risk may include determining and validating a CVD risk score using a variety of clinical data accessible to a clinician or available in an electronic system. For example, clinical characteristics and data may be included in electronic health records or health insurance claims data.

[0077] The disclosed method and algorithm can provide a validated CVD risk score with prognostic and / or outcome prediction utility.Such method and algorithm for CVD risk score can combine the use of clinical features or data with RA biomarkers.CVD risk score can be used to assess RA patients' CVD risk, recommend treatment, identify subjects who benefit from treatment, monitor patient's response to treatment, or prognosticate patients, and treat patients for inflammatory disease and / or CVD.

[0078] The methods of the present invention for determining CVD risk in RA patients can provide a surprisingly accurate CVD risk assessment.

[0079] In certain embodiments, accurate CVD risk assessment can advantageously expand the population of patients treated for CVD and / or RA. By expanding the population of patients treated for CVD and / or RA, the present invention can provide treatment to patients who may not have been treated with conventional methods or modalities for CVD risk. The expansion of the population of patients treated for CVD and / or RA can be indicated by reclassification of patients according to the CVD risk score thresholds of the present invention.

[0080] By including systemic inflammation, an important component of RA that contributes to CVD risk, the methods of the invention can expand the population of patients who can be evaluated or treated for CVD and / or RA. The methods of the invention can significantly improve the practice of medicine and treatment modalities for CVD risk in general, and CVD risk in RA patients in particular.

[0081] As used herein, the term "disease" refers to any disorder, condition, malady, or illness that manifests, for example, in an unregulated or improperly functioning organ, part, structure, or system of the body, resulting from, for example, genetic or developmental errors, infection, toxins, nutritional deficiencies or imbalances, toxicity, or unfavorable environmental factors.

[0082] As used herein, the term "autoimmune disease" encompasses any disease resulting from an immune response against substances and tissues normally present in the body. Examples of suspected or known autoimmune diseases include rheumatoid arthritis, early rheumatoid arthritis, axial spondyloarthritis, juvenile idiopathic arthritis, seronegative spondyloarthropathy, ankylosing spondylitis, psoriatic arthritis, antiphospholipid syndrome, autoimmune hepatitis, Behcet's disease, bullous pemphigoid, celiac disease, Crohn's disease, dermatomyositis, Goodpasture's syndrome, Graves' disease, Hashimoto's disease, idiopathic thrombocytopenic purpura, IgA nephropathy, and others. These include: Kawasaki disease, systemic lupus erythematosus, mixed connective tissue disease, multiple sclerosis, myasthenia gravis, polymyositis, primary biliary cirrhosis, psoriasis, scleroderma, Sjogren's syndrome, ulcerative colitis, vasculitis, Wegener's granulomatosis, temporal arteritis, Takayasu's arteritis, Henoch-Scholein purpura, leukocytic vasculitis, polyarteritis nodosa, Churg-Strauss syndrome, and mixed cryoglobulinemic vasculitis.

[0083] As used herein, the term "inflammatory disease" refers to any disease resulting from the biological response of vascular tissues to harmful stimuli, including but not limited to pathogens, damaged cells, irritants, antigens, and, in the case of autoimmune diseases, substances and tissues normally present in the body.

[0084] Some examples of inflammatory diseases include rheumatoid arthritis (RA), juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, atherosclerosis, asthma, autoimmune diseases, chronic inflammation, chronic prostatitis, glomerulonephritis, hypersensitivity disorders, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, transplant rejection, and vasculitis.

[0085] As used herein, the terms "cardiovascular disease," "cardiovascular disorder," and "CVD" can generally classify various conditions that affect the heart, heart valves, and vascular system of the body, e.g., arteries and veins, and encompass conditions, outcomes, or events including, but not limited to, arteriosclerosis, atherosclerosis, myocardial infarction (MI), acute coronary syndromes, angina, congestive heart failure, aortic aneurysm, aortic dissection, iliac or femoral aneurysm, pulmonary embolism, primary hypertension, atrial fibrillation, stroke, transient ischemic attack, systolic dysfunction, diastolic dysfunction, myocarditis, atrial tachycardia, ventricular fibrillation, endocarditis, arteriopathy, vasculitis, atherosclerotic plaque, vulnerable plaque, acute coronary syndromes, acute ischemic attack, sudden cardiac death, peripheral vascular disease, coronary artery disease (CAD), peripheral arterial disease (PAD), and cerebrovascular disease.

[0086] The diseases and medical conditions of the present disclosure include rheumatoid arthritis (RA) and cardiovascular disease (CVD). CVD can include atherosclerosis, coronary atherosclerosis, carotid atherosclerosis, and hypertension. For example, CVD can include pulmonary hypertension, labile hypertension, idiopathic hypertension, low renin hypertension, salt-sensitive hypertension, low renin hypertension, thromboembolic pulmonary hypertension, pregnancy-induced hypertension, renovascular hypertension, hypertension-dependent end-stage renal disease, hypertension associated with cardiovascular surgery, and hypertension with left ventricular (LV) hypertrophy, LV diastolic dysfunction, non-obstructive coronary heart disease, myocardial infarction, cerebral infarction, peripheral vascular disease, cerebrovascular disease, cerebral ischemia, angina including chronic angina, stable angina, unstable angina, and variant (Prinzmetal) angina, aneurysm, ischemic heart disease, thrombosis, platelet aggregation, platelet adhesion, smooth muscle contraction, and vascular endothelial dysfunction. These include myocyte proliferation, vascular or non-vascular complications associated with the use of medical devices, wounds associated with the use of medical devices, vascular or non-vascular wall injury, peripheral vascular disease, neointimal hyperplasia following percutaneous transluminal coronary angiography, vascular grafts, coronary artery bypass surgery, thromboembolic events, restenosis following angioplasty, coronary plaque inflammation, hypercholesterolemia, hypertriglyceridemia, embolism, stroke, shock, arrhythmias, atrial fibrillation or atrial flutter, thrombotic occlusion and reclusion cerebrovascular incidents, left ventricular dysfunction, cardiac hypertrophy, and hypertension with left ventricular hypertrophy and / or non-obstructive CVD.

[0087] Examples of CVD may include conditions related to oxidative stress, microvascular coronary heart disease, coronary endothelial dysfunction, left ventricular hypertrophy, dyspnea, inflammation, diabetes and chronic renal failure. Other CVD medical conditions are generally known to those skilled in the art.

[0088] As used herein, the term "remission" refers to a state of lack of disease activity in patients known to have a chronic disease that is usually not curable. As used herein, the term "sustained clinical remission" or "SC-REM" refers to a state of clinical remission that persists for at least 6 months as assessed based on clinical assessment, e.g., DAS28. As used herein, the term "functional remission" refers to a state of remission as assessed using functional assessment criteria, such as, but not limited to, the HAQ. Sustained remission can be used interchangeably with maintained remission.

[0089] Methods for clinically diagnosing diseases and medical conditions are known to those of skill in the art.

[0090] In general, ultrasound measurements of carotid intima-media thickness (IMT) can be used as a measure of CVD, e.g., atherosclerosis, and / or as a surrogate endpoint for determining regression or progression of atherosclerotic CVD, particularly carotid atherosclerosis.

[0091] In general, carotid IMT (CIMT) measures the thickness of the carotid artery wall to detect the presence of atherosclerosis or atherosclerotic burden and the progression of atherosclerosis, and can be a surrogate endpoint for evaluating the presence and progression of atherosclerotic CVD. Carotid IMT measurements can be obtained from one or more segments of the carotid artery, i.e., the common carotid artery, bifurcation, or internal carotid artery. In particular, the IMT of the common carotid artery (CCA) can be useful as a risk marker for atherosclerosis. See, for example, E. Vicenzini et al., J. Ultrasound Med. 2007, 26:427-432. The atherosclerotic burden in the artery, as measured by carotid IMT, can be associated with CVD risk and shown to predict fatal coronary death. For example, see JT Salonen and R. Salonen, Arterioscler.Thromb.1991,11:1245-1249; LE Chambless et al., Am.J.Epidemiol.1997,146: and HN Hodis et al., Ann.Intern.Med.1998,128:262-269. Absolute intima-media thickness is associated with the risk of clinical coronary events. Thus, carotid IMT measurements can be used to determine the atherosclerotic burden of a subject, and changes in IMT can also be used to evaluate changes in atherosclerotic burden and the progression of atherosclerosis.

[0092] In addition to treating RA, embodiments of the present invention further contemplate methods of treating CVD in RA.

[0093] Methods for treating CVD in RA may include one or more steps of administering a CVD drug, administering a cholesterol-lowering drug, administering a blood flow increasing drug, administering a cardiac rhythm regulating drug, administering a cardiac rhythm stabilizing drug, and / or administering an agent that reduces blood blockage.

[0094] Methods for treating CVD in RA can include a treatment regimen being administered to a subject.

[0095] Examples of treatment regimens for CVD in RA can include treatment regimens administered at the time the sample was obtained. The administered treatment regimen may have been a treatment regimen for RA, CVD, or both.

[0096] An example of a treatment regimen for CVD in RA may include the cessation of a treatment regimen administered to the subject at the time the sample was obtained. The treatment regimen administered may have been a treatment regimen for RA, CVD, or both.

[0097] An example of a treatment regimen for CVD in RA may include tapering the treatment regimen administered to the subject at the time the sample was obtained. The treatment regimen administered may be a treatment regimen for RA, CVD, or both.

[0098] Examples of CVD drugs include beta-blockers, ACE inhibitors, aldosterone inhibitors, angiotensin II receptor blockers, calcium channel blockers, cholesterol-lowering drugs, diuretics, inotropes, electrolyte supplements, PCSK9 inhibitors, and vasodilators.

[0099] Examples of CVD drugs include metoprolol, acebutolol, atenolol, bisoprolol and propranolol.

[0100] Examples of CVD drugs include lisinopril, enalapril, fosinopril, moexipril, perindopril, quinapril, ramipril, and tranolapril.

[0101] Examples of CVD drugs include spironolactone and eplerenone.

[0102] Examples of CVD drugs include azilsartan, eprosartan, irbesartan, telmisartan, candesartan, losartan, olmesartan and valsartan.

[0103] Examples of CVD drugs include amlodipine, felodipine, isradipine, nicardipine, nifedipine, diltiazem, nisoldipine and verapamil.

[0104] Examples of CVD drugs include atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin.

[0105] Examples of CVD drugs include bumetanide, ethacrynic acid, furosemide, torsemide, chlorothiazide, chlorthalidone, hydrochlorothiazide, metolazone, indapamide, amiloride, and triamterene.

[0106] Examples of CVD drugs include amrinone, digoxin, dobutamine, dopamine, inamrinone, inotropin, lanoxin, and milrinone.

[0107] Examples of CVD drugs include alirocumab and evolocumab.

[0108] Examples of CVD drugs include alprostadil, riociguat, hydralazine, minoxidil, nesiritide, and nitroprusside.

[0109] Examples of CVD drugs include aspirin, clopidogrel, warfarin, potassium supplements, and calcium supplements.

[0110] Methods for treating CVD in RA may include one or more of the steps of surgery, percutaneous coronary intervention, coronary artery bypass surgery, performing heart valve repair or replacement surgery, and / or performing bariatric surgery.

[0111] Methods for treating CVD in RA may include one or more of cardiac rehabilitation, therapeutic physical programs, and / or implementing dietary modifications or restrictions.

[0112] Methods for treating CVD in RA can include steps for treating risk factors for CVD, including one or more of smoking cessation, diabetes treatment, and / or hypertension treatment.

[0113] Methods for treating CVD in RA may include effecting one or more symptomatic relief, reducing the risk of recurrence, reducing the severity of recurrence, reducing heart failure or heart attacks, and / or reducing stroke.

[0114] The method for treating RA may include administering an RA drug. Examples of RA drugs include administering an NSAID drug, administering a steroid drug, administering a disease-modifying antirheumatic drug (DMARD), and administering a biological DMARD.

[0115] Examples of RA medications include ibuprofen, naproxen, and meloxicam.

[0116] Examples of RA drugs include prednisone.

[0117] Examples of RA drugs include methotrexate, leflunomide, hydroxychloroquine and sulfasalazine.

[0118] Examples of RA drugs include abatacept, adalimumab, anakinra, baricitinib, certolizumab, etanercept, golimumab, infliximab, rituximab, sarilumab, tociluzumab, and tofacitinib.

[0119] Methods for treating RA may include steps for performing surgery, synovectomy, tendon repair surgery, joint fusion surgery, joint replacement surgery and bariatric surgery.

[0120] Methods for treating RA may include steps to implement a therapeutic physical program, and / or dietary modifications or restrictions.

[0121] The methods for treating RA can include a step for monitoring the subject's response to the treatment.

[0122] Treatments for CVD may include, but are not limited to, anticoagulants, antiplatelet agents, thrombolytic agents, antithrombotic agents, antiarrhythmic agents, agents that prolong repolarization, antihypertensive agents, vasodilators, antihypertensive agents, diuretics, inotropic agents, antianginal agents, and the like.

[0123] Examples of anticoagulants include acenocoumarol, ancrod, anisindione, bromindione, chlorindione, coumetalol, cyclocoumarol, dextran sulfate sodium, dicumarol, diphenadione, ethyl biscoumarol, ethylidene dicumarol, fluindione, heparin, hirudin, sodium liaporate, oxazidione, pentosan polysulfate, phenindione, phenprocoumon, phosvitin, picotamide, thiochromarol, and warfarin.

[0124] Examples of antiplatelet agents include aspirin, dextran, dipyridamole (persantin), heparin, sulfinpyranone (anturane), clopidine, and ticlopidine (ticlid).

[0125] Examples of thrombolytic agents include tissue plasminogen activator (activase), plasmin, pro-urokinase, urokinase (abokinase), streptokinase (streptase), and anistreplase / APSAC (eminase).

[0126] To identify additional therapeutic agents or drugs suitable for a particular subject, test samples from the subject can also be exposed to the therapeutic agent or drug, and the level of one or more biomarkers can be determined. The level of one or more biomarkers can be compared to samples obtained from the subject before and after treatment or exposure to the therapeutic agent or drug, or compared to samples obtained from one or more subjects who have shown improvement in inflammatory disease status or activity (e.g., clinical parameters or traditional laboratory risk factors) as a result of such treatment or exposure.

[0127] The term "administering" as used herein includes, but is not limited to, placing a composition on a subject by a method or route that results in at least partial localization of the composition at a desired site so that a desired effect occurs. Routes of administration include both local administration and systemic administration. Generally, local administration results in greater composition delivery to a specific location than to the entire body of a subject, while systemic administration results in delivery to essentially the entire body of a subject. "Administering" also includes performing physical actions on a subject's body, including massage, physical therapy, and the like.

[0128] In a further aspect, the present invention contemplates a method for assessing a particular risk of cardiovascular disease in a patient with an inflammatory disease. The inflammatory disease can be RA. A further method is disclosed for recommending a particular treatment to a subject with an inflammatory disease, which can be RA and at risk of cardiovascular disease (CVD). A further method includes identifying a particular subject with an inflammatory disease and at risk of cardiovascular disease (CVD) that will benefit from treatment. The present disclosure includes a particular method for treating CVD in a subject with an inflammatory disease and in need of treatment for cardiovascular disease (CVD). A further method includes monitoring a particular response to treatment of a subject with an inflammatory disease and at risk of CVD. A further method includes prognosing a subject with an inflammatory disease and at risk of CVD.

[0129] The method of the present invention can include an efficient and accurate method for predicting CVD event risk in RA patients.The method can include evaluating systemic inflammation by using biomarkers and other factors that reflect the disease activity and complexity of RA, including associated CVD risk.The method disclosed herein can be efficiently implemented at the point of care of RA, and can expand the patient population that is included in the treatment.

[0130] An embodiment of the present invention contemplates assessing the risk of CVD in a subject with an inflammatory disease by determining a CVD risk value for the subject.

[0131] The CVD risk value and the underlying VECTRA-CVD score can be determined by assaying biomarker levels and collecting clinical patient data for RA patients. The biomarker levels are combined with the clinical data by application of an interpretation function to provide a score from which the CVD risk value and the underlying VECTRA-CVD score can be derived.

[0132] In some aspects, the CVD risk value can be determined using a VECTRA-CVD score. The VECTRA-CVD score can be determined based on an adjusted VECTRA score that can be combined with clinical parameters and additional adjustments for each of the leptin, TNFRI, and MMP3 biomarkers. The adjusted VECTRA score can be determined based on an MBDA score that utilizes several VECTRA biomarkers, along with certain clinical variables and additional adjustments for the leptin biomarker.

[0133] In some aspects, a quantitative measure of risk in a subject having an inflammatory disease can be measured by determining the levels of two or more VECTRA biomarkers in a sample from the subject and then applying an interpretation function to convert the biomarker levels into an MBDA score. The MBDA score can be adjusted using certain clinical variables, and additional adjustment terms for the leptin biomarker, to obtain an adjusted VECTRA score. The adjusted VECTRA score can be combined with clinical parameters and additional adjustment terms for each of the leptin, TNFRI, and MMP3 biomarkers to provide an overall VECTRA-CVD score. A subject's CVD risk value can be derived from the VECTRA-CVD score.

[0134] A CVD risk value as well as the underlying VECTRA-CVD score can be determined in a training phase, followed by a validation phase using clinical patient data of RA patients.

[0135] A wide range of candidate variables can be evaluated and used in determining the CVD risk value. A training and / or validation phase can determine the final variables used to determine the CVD risk value from among the wide range of candidate variables.

[0136] In the training phase, interpretation functions can be applied via univariate and bivariate analysis using clinical patient data of RA patients to provide associations between CVD risk values ​​and their underlying VECTRA-CVD scores and clinical outcomes in RA patients.

[0137] In the validation phase, interpretation functions can be applied via univariate and bivariate analysis using clinical patient data of RA patients to provide validation of the CVD risk value and its underlying VECTRA-CVD score with respect to clinical outcomes in RA patients. Validation of the CVD risk value can confirm the accuracy of the CVD risk value and its underlying VECTRA-CVD score.

[0138] In the training and / or validation phases, the final variables to be used may be determined by use or application of an interpretation function. The interpretation function may select the final variables to be used from a set of candidate variables. The interpretation function may select a weight to be applied to each of the selected variables.

[0139] In certain aspects, the MBDA scores derived as described herein can vary based on a set of values ​​selected by an expert. For example, the scores can be set so that values ​​can range from 0 to 100, and the difference between two scores is at least one point. The expert can then assign risk based on the values ​​by establishing a correlation with patient data.

[0140] As used herein, the term "sample" can refer to a biological sample that can be isolated from a subject. Samples can include, but are not limited to, single or multiple cells, cell fragments, aliquots of bodily fluids, whole blood, platelets, serum, plasma, red blood cells, white blood cells or leucocytes, endothelial cells, tissue biopsies, synovial fluid, lymphatic fluid, peritoneal fluid, and interstitial or extracellular fluid. The term "sample" also encompasses the fluid in the space between cells, including synovial fluid, gingival crevicular fluid, bone marrow, cerebrospinal fluid (CSF), saliva, mucous membranes, sputum, semen, sweat, urine, or any other bodily fluid. The term "blood sample" can refer to whole blood or any fraction thereof, including blood cells, red blood cells, white blood cells or leucocytes, platelets, serum, and plasma. Samples may be obtained from a subject by means including, but not limited to, venipuncture, excretion, ejaculation, massage, biopsy, needle aspiration, lavage, scraping, surgical incision, or intervention, or other means known in the art.

[0141] As used herein, the term "subject" may be, for example, a human or a mammal. The term "patient" may refer to a human patient, which may be a subject. As used herein, the term "mammal" includes, but is not limited to, humans, non-human primates, dogs, cats, mice, rats, cows, horses, and pigs. Non-human mammals may be advantageously used as subjects representing animal models of inflammation. The subject may be male or female. The subject may be a person who has previously been diagnosed or identified as having an inflammatory disease. The subject may be a person who has already undergone or is undergoing a therapeutic intervention for an inflammatory disease. The subject may also be a person who has not previously been diagnosed as having an inflammatory disease. For example, the subject may be a person who exhibits one or more symptoms or risk factors of an inflammatory condition, or a subject who does not exhibit symptoms or risk factors of an inflammatory condition, or a subject who may be asymptomatic for an inflammatory disease.

[0142] As used herein, the term "interpretation function" can refer to one or more biostatistical tools that can provide a predictive method for assessing a patient's risk and / or outcome. The biostatistical tools can utilize a patient's clinical and / or biomarker data to identify or derive an accurate risk algorithm that reflects a significant association between a patient's outcome and a risk value.

[0143] Biostatistical tools can generate risk algorithms that accurately predict a patient's risk of disease based on clinical and / or biomarker data from a reference group.

[0144] The reference group may include patients with disease activity. In certain aspects, the reference group may include patients without disease activity.

[0145] In further aspects, the reference group may include patients with active disease, patients without active disease, and patients who have not been diagnosed with the disease.

[0146] In certain embodiments, the reference group may include patients who have been tested for disease activity.

[0147] In a further embodiment, the reference group may include patients who have been tested for rheumatoid arthritis (RA) activity. The test may have been performed as a routine test, as a clinical research test, as a genetic test, or as an MBDA test.

[0148] In further embodiments, the reference group may include patients who have been tested for rheumatoid arthritis (RA) and / or cardiovascular disease (CVD) activity. The tests may have been performed as routine tests, as clinical research tests, as genetic tests, or as MBDA tests.

[0149] In certain aspects, the reference group can be Medicare patients.

[0150] In certain embodiments, the reference group may be patients in a healthcare database.

[0151] Interpretation functions may be known in the art for calculating and validating predictive clinical methods.

[0152] In a further embodiment, the reference group may be clinical training data and / or clinical validation data.

[0153] As used herein, the term "score" can refer to a value or set of values ​​selected to provide a quantitative measure of a variable or a characteristic of a subject's condition and / or to identify, differentiate, or otherwise characterize a subject's condition. Values, including scores, can be based on quantitative data leading to a measured amount of one or more sample components obtained, for example, from a subject, or from clinical parameters, or from clinical evaluation, or any combination thereof. In certain embodiments, a score can be derived from a single component, parameter, or assessment, while in other embodiments, a score can be derived from multiple components, parameters, and / or assessments. A score can be determined using an interpretation function. A "change in score" can refer, for example, to the absolute change in score from one time point to the next, or the percentage change in score, or the change in score per unit time (e.g., the rate of score change).

[0154] As used herein, the term "dataset" can refer to a set of numerical values ​​obtained from the evaluation of a sample (or a population of samples) under desired conditions. The values ​​of the dataset can be obtained, for example, by experimentally obtaining measurements from the samples and constructing the dataset from these measurements; or alternatively, by obtaining the dataset from a service provider, such as a laboratory, or from a database or server on which the dataset is stored.

[0155] As used herein, the term "difference" can refer to an increase or a decrease.

[0156] As used herein, the term "statistically significant" can refer to an observed change that is greater than expected to occur by chance alone. Statistical significance can be determined by any of a variety of methods known in the art. An example of a commonly used measure of statistical significance is the p-value. A result can be considered statistically significant (not by chance) at a p-value of 0.05 or less, or in some embodiments, at a p-value of 0.01 or less. In general, the p-value can be a measure of the probability of obtaining a result, and the p-value can be compared for different results when obtained under similar circumstances.

[0157] The method of the present invention contemplates the use of a "multi-biomarker disease activity score" (MBDA score). As used herein, the MBDA score can use various biomarkers to provide a quantitative measure of a subject's inflammatory disease activity or inflammatory disease state. The biomarkers can be used to derive an MBDA score using an interpretation function according to the present teachings. Two or more biomarkers can be used alone or in combination with the clinical parameters and / or clinical assessments described herein. In some embodiments, the MBDA score can be a quantitative measure of autoimmune disease activity. In certain embodiments, the MBDA score can be a quantitative measure of RA disease activity.

[0158] Biomarkers that may be useful in deriving the MBDA score include, but are not limited to, leptin (LEP), tumor necrosis factor receptor superfamily, member 1A (TNFRSF1A expressed TNFR1), matrix metallopeptidase 3 (stromelysin 1, progelatinase) (MMP3), C-reactive protein, pentraxin related (CRP), interleukin 6 (interferon, beta 2) (IL6), serum amyloid A1 (SAA1), chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1), epidermal growth factor (beta-urogastron) (EGF), vascular cell adhesion molecule 1 (VCAM1), matrix metallopeptidase 1 (interstitial collagenase) (MMP1), resistin (RETN), and vascular endothelial growth factor A (VEGFA).

[0159] The MBDA score can be a clinically validated tool that quantifies 12 serum protein biomarkers to assess disease activity in adult patients with rheumatoid arthritis (RA). See Curtis JR, et al., Arthritis Care Res. 2012, Vol. 64, pp. 1794-803. The 12 MBDA serum protein biomarkers can be leptin, TNFR1, MMP-3, CRP, IL-6, SAA, YKL-40, EGF, VCAM-1, MMP-1, resistin, and VEGF-A.

[0160] The quantity referred to as the MBDA score "MDBA 1.0" is described in U.S. Patent No. 9,200,324, which is incorporated herein by reference in its entirety. "MBDA 2.0" or "Adjusted MBDA" is described in Curtis et al., Rheumatology, Vol. 58(5), May 2019, pp. 874-883, which is incorporated herein by reference in its entirety. Here, we have found that the MBDA score is calculated based on Formula I: We refer to the "Adjusted MBDA" score as being the "Leptin-Adjusted MBDA" score of Curtis et al., denoted by TIFF2024161429000002.tif62128, where gender equals 1 if the patient is male and 0 if female. The Adjusted MBDA score is rounded to the nearest integer. MBDA and Adjusted MBDA scores range from 1 to 100.

[0161] The adjusted MBDA score of the present disclosure may include biomarker data from three or more biomarkers from a set including, but not limited to, leptin, TNFR1, MMP-3, CRP, IL6, SAA, YKL40, EGF, VCAM1, MMP1, resistin, and VEGFA.

[0162] As used herein, the name of the gene, for example TNFRSF1A, also refers to the expressed protein marker, TNFR1, as well as the mRNA.

[0163] In some embodiments, the invention includes methods of measuring biomarker levels in a sample from a subject to generate protein level data for LEP, TNFR1, and MMP3 that are combined with clinical data to produce an adjusted MBDA score.

[0164] In a further aspect, the invention includes a method of measuring biomarkers in a sample from a subject to generate protein level data for LEP, TNFR1, MMP3, and one or more additional protein markers selected from the set including CRP, IL6, SAA1, CHI3L1, EGF, VCAM1, MMP1, RETN and VEGFA.

[0165] In a further aspect, the invention includes methods for measuring biomarkers in a sample from a subject to generate protein level data for LEP, TNFR1, and MMP3 that can be combined with clinical data including age, smoking, diabetes, hypertension, and / or CVD history to determine CVD risk.

[0166] In a further aspect, the present invention includes a method of measuring biomarkers in a sample from a subject to generate protein level data for one or more additional protein markers selected from the set including LEP, TNFR1, MMP3, and CRP, IL6, SAA1, CHI3L1, EGF, VCAM1, MMP1, RETN and VEGFA, which can be combined with clinical data including age, smoking, diabetes, hypertension, and / or CVD history to determine CVD risk.

[0167] In some embodiments, the present invention includes methods of measuring biomarkers in a sample from a subject to generate protein level data for one or more protein markers selected from the set including LEP, TNFRSF1A, MMP3, CRP, IL6, SAA1, CHI3L1, EGF, VCAM1, MMP1, RETN and VEGFA.

[0168] In a further aspect, the invention includes a method of measuring biomarkers in a sample from a subject to generate protein level data for at least two protein markers selected from the set including LEP, TNFRSF1A, MMP3, CRP, IL6, SAA1, CHI3L1, EGF, VCAM1, MMP1, RETN and VEGFA.

[0169] In a further aspect, the invention includes a method of measuring biomarkers in a sample from a subject to generate protein level data for at least three protein markers selected from the set including LEP, TNFRSF1A, MMP3, CRP, IL6, SAA1, CHI3L1, EGF, VCAM1, MMP1, RETN and VEGFA.

[0170] In some embodiments, the present invention includes methods of measuring biomarkers in a sample from a subject to generate protein level data for at least four protein markers selected from the set including LEP, TNFRSF1A, MMP3, CRP, IL6, SAA1, CHI3L1, EGF, VCAM1, MMP1, RETN and VEGFA.

[0171] In a further aspect, the invention includes a method of measuring biomarkers in a sample from a subject to generate protein level data for at least five protein markers selected from the set including LEP, TNFRSF1A, MMP3, CRP, IL6, SAA1, CHI3L1, EGF, VCAM1, MMP1, RETN and VEGFA.

[0172] In certain aspects, the present invention includes a method of measuring biomarkers in a sample from a subject to generate protein level data for at least six protein markers selected from the set including LEP, TNFRSF1A, MMP3, CRP, IL6, SAA1, CHI3L1, EGF, VCAM1, MMP1, RETN and VEGFA.

[0173] Any of the above sets of biomarkers can be combined with clinical data including age, smoking, diabetes, hypertension and / or CVD history to determine CVD risk.

[0174] Generally, population-based studies in RA that study hard endpoints, including myocardial infarction (MI), can be difficult because the prevalence of RA is relatively low, and outcome event rates limit statistical power.In some embodiments, administrative data from health insurance and insurers can have high validity for studying large cohorts of RA patients.Although these data sources often lack clinical evaluation of RA, the results of laboratory tests that measure RA disease activity can provide objective measurements that can augment claims data.

[0175] As used herein, the term "performance" can refer to, for example, the quality and overall usefulness of a model, algorithm, or diagnostic or prognostic test.Factors considered in model or test performance include, but are not limited to, the clinical and analytical accuracy of the test, the usage characteristics, such as the stability of reagents and various components, the ease of use of the model or test, the health or economic value, and the relative cost of various reagents and components of the test.Performing can refer to the act of performing a function.

[0176] As used herein, the term "population" can refer to a grouping of subjects with similar specified characteristics. Grouping can be, for example, but not limited to, according to clinical parameters, clinical evaluations, treatment regimens, disease states (e.g., diseased or healthy), levels of disease activity, and levels of CVD risk. In the context of using MBDA scores in comparing risks between populations, an aggregate value can be determined based on the observed MBDA scores of subjects in the population at a particular time point in a longitudinal study, for example. The aggregate value can be based on any mathematical or statistical formula known in the art that is useful, for example, for arriving at a meaningful aggregate value from a collection of individual data points (e.g., mean, median, median of mean).

[0177] As used herein, the term "predictive model" can refer to a "multivariate model" or "model," which can be a mathematical structure developed using a statistical algorithm or an algorithm to classify a data set. As used herein, the term "predicting" can refer to generating a value for a data point without actually performing a clinical diagnostic procedure that would normally or otherwise be required to generate that data point. When used in the context of modeling, "predicting" should not be understood to refer solely to the power of a model to predict a particular outcome. A predictive model can include an interpretation function. For example, a predictive model can be created by utilizing one or more statistical tools or methodologies to convert a data set of observed data into a prediction of a risk score associated with a disease state of interest.

[0178] As used herein, the term "prognosis" can refer to a prediction regarding the likely outcome of a disease. Prognosis estimates are useful, for example, in determining an appropriate treatment regimen for a subject.

[0179] As used herein, the term "recommend" can refer to recommending a treatment regimen to a subject, or excluding (i.e., not recommending) a particular treatment regimen. Such a recommendation, together with other information, can serve as a basis for a clinician to apply a particular treatment regimen to an individual subject.

[0180] In some embodiments, the interpretation function may use one or more of a variety of biostatistical tools. Several biostatistical tools and methodologies are known in the art.

[0181] Examples of biostatistical tools include, among others, survival regression analysis, Cox proportional hazards, Box-Cox transformation, clustering machine learning, hierarchical clustering analysis, centroid clustering, distributional clustering, density clustering, cluster data mining, analysis of variance (ANOVA), AdaBoosting, classification and regression trees (CART), boosted CART, random forests (RF), recursive partitioning trees (RPART), curd-and-whey (CW), curd-and-whey-Lasso, principal component analysis (PCA), factor rotation analysis, linear discriminant analysis (LDA), Eigengene linear discriminant analysis (ELDA), quadratic discriminant analysis, discriminant function analysis (DFA), hidden Markov models, kernel density estimation, kernel partial least squares algorithm, kernel matching pursuit algorithm, kernel Fisher discriminant analysis algorithm, kernel principal component analysis algorithm; linear regression, stepwise regression, incremental stepwise regression, Lasso shrinkage selection method, Elastic Net regularization and selection, Lasso and Elastic Net regularized generalized linear model, logistic regression (LogReg), K nearest neighbors (KNN), nonlinear regression, classification, neural networks, partial least squares, rule-based classification, shrink centroids (SC), stratified inverse regression, product model data exchange standard application adaptation construct (StepAIC), super principal component (SPC) regression, support vector machine (SVM), and recursive support vector machine (RSVM), as well as combinations thereof.

[0182] Additionally, clustering algorithms known in the art can be useful in determining subgroups of subjects. Examples of clustering algorithms include clustering machine learning, hierarchical clustering analysis, centroid clustering, distribution clustering, density clustering, cluster data mining, and combinations thereof.

[0183] Examples of biostatistical tools include logistic regression, which can be used for dichotomous response variables, e.g., treatment 1 vs. treatment 2. Logistic regression can be used for both linear and non-linear aspects of the data variables and provides interpretable odds ratios.

[0184] Examples of biostatistical tools include discriminant function analysis (DFA), which can use a set of analytes as variables (roots) to distinguish between two or more naturally occurring groups. DFA can be used to test analytes that differ significantly between groups. Forward stepwise DFA can be used to select the set of analytes that maximally discriminate between the groups studied. Specifically, at each step all variables can be reviewed to determine which maximally discriminate between the groups. This information can then be included in a discriminant function with a root displayed, which can be a formula consisting of a linear combination of analyte concentrations for the prediction of group membership. The discriminability of the final formula can be observed as a line plot of the root values ​​obtained for each group. This approach can identify groups of analytes whose profiles can be delineated using changes in concentration levels to diagnose and evaluate treatment efficacy. DFA models can also create arbitrary scores that can classify new subjects as either "healthy" or "diseased." To facilitate use of this score in the medical community, the score can be rescaled so that a value of 0 indicates a healthy individual and a score greater than 0 indicates increased risk.

[0185] Examples of biostatistical tools include classification and regression trees (CART), which can perform logical partitioning (if / then) of data to create decision trees. All observations entering a given node can be classified according to the most common outcome at that node. CART results can be interpreted by following a series of if / then tree branches until a classification is reached.

[0186] Examples of biostatistical tools include support vector machines (SVMs), which can classify subjects into two or more classes. Examples of classes include a set of treatment options, a set of diagnostic options, or a set of prognostic options. Each subject can be assigned to a class based on its similarity (or distance) to subjects in a training dataset, from which the correct class assignment for each subject may be known. A measure of similarity between known and new subjects may be determined using support vectors that define regions in a potentially high dimensional space (>R6).

[0187] Examples of biostatistical tools include the methods used in the present invention, which may include a process of bootstrap aggregation or "bagging." In a first step, a given data set may be randomly resampled a specified number of times (e.g., thousands) to effectively provide that number of new data sets. This may be called a "bootstrap resample" of the data, each of which may then be used to build a model. In the example of a classification model, the class of every new observation may then be predicted by the number of classification models created in the first step. The final class decision may be based on a "majority vote" of the classification models. That is, the final classification call may be determined by counting the number of times a new observation is classified into a given group and taking the majority classification (33%+ for a 3-class system). In the example of a logistic regression model, if the logistic regression is bagged 1000 times, there will be 1000 logistic models, each providing the probability of a sample belonging to class 1 or 2.

[0188] Examples of biostatistical tools include the methods of the present invention, which may include Curd and Whey (CW), which uses Ordinary Least Squares (OLS) as a predictive modeling method. See L. Breiman and JH Friedman, J. Royal. Stat. Soc. B 1997, 59(1):3-54. This method can exploit the correlation between response variables to improve prediction accuracy compared to the usual procedure of performing individual regressions of each response variable against a common set of predictor variables X. In CW, Y=XB*S, where Y=(y kj ), where k is the kth patient, j is the jth response (j=1 for TJC, j=2 for SJC, etc.), B can be obtained using OLS, and S can be a reduced matrix calculated from the canonical coordinate system. Another method could be combined curd-and-whey and Lasso (CW-Lasso). Instead of using OLS to obtain B as in CW, Lasso can be used here, and the parameters can be adjusted depending on the Lasso approach.

[0189] Examples of biostatistical tools include biomarker selection techniques (e.g., forward, backward, or stepwise selection methods), which may be used in combination or for complete enumeration of all potential panels of a given size, or genetic algorithms, or may themselves include biomarker selection methodologies in their own techniques. These techniques can be combined with information criteria, such as Akaike Information Criterion (AIC), Bayesian Information Criterion (BIC), or cross-validation, to quantify the trade-off between the inclusion of additional biomarkers and model improvement and minimize overfitting. The resulting predictive models can be validated in other studies, or cross-validated in the study on which they were originally trained, using techniques such as Leave-One-Out (LOO) and 10-fold cross-validation (10-Fold CV).

[0190] As an example, the interpretation function can provide an MBDA score derived using one or more of the biostatistical tools described above, which can be represented by Equation II, with reference to Biomarkers 1 (BM1)-5 (BM5): TIFF2024161429000003.tif18134

[0191] The MBDA score of a RA subject obtained with a known clinical assessment (e.g., DAS28 score) can then be compared with those known assessments to determine the level of correlation between the two assessments, and thus the accuracy of the MBDA score and its underlying predictive model.

[0192] As an example, one or more steps of the methods of the invention may be derived by one or more of the following steps: obtaining biomarker data for a subject, selecting clinical parameters to combine with the biomarker results, selecting additional biomarker conditions to combine with the clinical parameters, calculating a subject's risk score from one or more biomarkers and one or more clinical conditions together with clinical training data using an interpretation function, calculating and deriving a subject's risk score algorithm from the biomarkers and one or more clinical conditions together with clinical training data using one or more biostatistical tools, calculating a subject's risk score from the biomarkers and one or more clinical conditions together with clinical validation data using an interpretation function, calculating and deriving a subject's risk score algorithm from the biomarkers and one or more clinical conditions together with clinical validation data using one or more biostatistical tools, and / or applying the risk score algorithm to clinical and / or biomarker data from a subject in need thereof.

[0193] As an example, one or more steps of the methods of the invention may be using the risk score to assess a particular risk of cardiovascular disease in a patient with an inflammatory disease, using the risk score to recommend a particular treatment for a subject with an inflammatory disease, using the risk score to identify a particular subject with an inflammatory disease and at risk of cardiovascular disease (CVD) who will benefit from treatment, using the risk score to treat cardiovascular disease (CVD) in a subject with an inflammatory disease and in need of treatment, using the risk score to monitor a particular response to treatment of a subject with an inflammatory disease and at risk of having CVD, and using the risk score to prognose a subject with an inflammatory disease and at risk of having CVD.

[0194] In some embodiments of the present teachings, it may not be necessary to compare the MBDA score to any predetermined "reference," "normal," "control," "standard," "healthy," "pre-disease," or other similar indices for the MBDA score to provide a quantitative measure of a subject's risk.

[0195] In further aspects of the present teachings, the amount of biomarkers can be measured in a sample and used to derive an MBDA score, which can then be compared to "normal" or "control" levels or values, utilizing techniques such as, for example, reference or discrimination limits or risk-defining thresholds, to define cutoff points and / or outliers for CVD risk. Normal levels, in this case, can be levels of one or more biomarkers, or a combined biomarker index, typically found in subjects not suffering from the inflammatory disease under evaluation. Other terms for "normal" or "control" are, for example, "reference," "index," "baseline," "standard," "healthy," and "pre-disease." Such normal levels can vary based on whether a biomarker is used alone or in a formula combined with other biomarkers to output a score. Alternatively, normal levels can be a database of biomarker patterns from previously tested subjects who did not convert to the inflammatory disease under evaluation over a clinically relevant period of time. Reference (normal, control) values ​​can also be derived, for example, from control subjects or populations of known risk.

[0196] In some embodiments of the present teachings, the reference value can be derived from one or more subjects exposed to disease treatment, or from one or more subjects with low risk, or from subjects that have shown improvement as a result of exposure to treatment.In some embodiments, the reference value can be derived from one or more subjects that are not exposed to treatment.For example, samples can be collected from (a) subjects that have received initial treatment and (b) subjects that have received subsequent treatment to monitor the progress of treatment.The reference value can also be derived from indexes calculated from risk algorithms or population studies.

[0197] The terms "normal", "control" and "healthy" as used herein can generally refer to a subject or individual who does not have, has not been diagnosed with, or is asymptomatic for a particular disease or disorder. The terms can also refer to a sample obtained from such a subject or individual. The disease or disorder being analyzed or compared can be what determines whether a subject is a "control" in that context. For example, if the level of a particular serum marker is obtained from an individual who is known to have RA but has not been diagnosed with CVD and is asymptomatic for CVD, the subject can be an "RA subject". The level of the marker thus obtained from the RA subject can be compared to the level of the same marker from a subject who has been diagnosed with RA but is known not to have common CVD and not to be a CVD progressor, i.e., a "normal subject". Thus, "normal" in this example refers to the CVD state of the subject, not the RA state.

[0198] As used herein, the term "accuracy" can refer to the degree to which a measured or calculated value corresponds to its actual value.In clinical trials, "accuracy" can relate to the ratio of actual results (true positive or true negative, the subject is correctly classified as having disease or as healthy / normal, respectively) to incorrectly classified results (false positive or false negative, the subject is incorrectly classified as having disease or as healthy / normal).

[0199] As used herein, the terms "sensitivity", "specificity", "positive predictive value (PPV)", "AUC", "negative predictive value (NPV)", "likelihood" and "odds ratio" can refer to mathematical characteristics that can reflect medical accuracy. "Analytical accuracy" in the context of this disclosure can refer to the reproducibility and predictability of the measurement process. Analytical accuracy can be aggregated in measurements such as the coefficient of variation (CV) and in tests of matching and calibration of the same sample or control at different times or by different assessors, users, instruments, and / or reagents. See, for example, R. Vasan, Circulation 2006, 113(19):2335-2362.

[0200] In some embodiments, the MBDA test can be a panel of 12 biomarkers that have been validated against DAS28 in multiple RA cohorts of seropositive and seronegative patients treated with a variety of RA therapies.

[0201] Biomarkers included in the MBDA may reflect the biology of RA and may include cytokines, acute phase reactants, growth factors, matrix metalloproteinases, and adipokines.

[0202] The 12 biomarkers can be weighted as a linear combination according to a published algorithm (Vectra 2.0) to generate a single score on a scale of 1 to 100.

[0203] For clinical interpretation, this numerical score can be mapped to RA disease activity categories of low, moderate and high disease activity, or low, borderline, moderate and high.

[0204] In addition to both the overall MBDA score and its 12 component biomarkers, various clinical parameters can be included in the predictive model based on their expected association with CVD risk.

[0205] Candidate parameters for CVD risk may include age, sex, race, diagnosis and medication of diabetes, hypertension, hyperlipidemia, tobacco use, cardiovascular disease other than MI or stroke, e.g., history of angina or acute coronary syndrome without MI, atrial fibrillation, peripheral vascular disease, use of certain RA medications such as methotrexate, other conventional synthetic disease-modifying antirheumatic drugs, biologics, Janus kinase inhibitors, glucocorticoids, and nonsteroidal anti-inflammatory drugs.

[0206] In further aspects, the present invention provides various methods for identifying, assaying, determining and predicting CVD risk. The development of an accurate final treatment prognosis may require several stages of development, screening and / or drawing of intermediate conclusions.

[0207] In some aspects, development of an accurate final treatment prognostic or predictive model may involve feature selection and model building using a training dataset.

[0208] In some embodiments, model building can include selection made according to the Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD) guidelines.

[0209] In further embodiments, the cohort may be randomly split 2:1 into separate training and testing datasets. Feature selection and model building may be performed on the training data.

[0210] In a further aspect, the candidate features can be characterized descriptively.

[0211] For feature characterization, means (SD) can be calculated for continuous predictors and percentages can be calculated for categorical predictors, allowing stratification of patients according to whether or not they have a CVD event.

[0212] In a further aspect, the VECTRA-CVD score can include a hyperbolic tangent function. The parameters of the hyperbolic tangent transformation can be selected based on maximum likelihood estimation. The parameters of the hyperbolic tangent transformation can be updated at each step of model construction.

[0213] In a further aspect, features can be initially screened using elimination regression with an alpha value of 0.05. Features can be prioritized based on their association with the results of the univariate analysis.

[0214] In some embodiments, the final model can be selected by examining its performance against a model developed using only the training data. Several factors can be used in selecting the final model, including model discrimination, calibration, parsimony, and the expected feasibility of collecting covariates required in a routine clinical care setting.

[0215] In certain embodiments, statistical analysis can be performed by categorizing risks into various risk groups.

[0216] For example, in some embodiments, patients can be grouped into three risk groups according to their predicted risk of CVD in three years.

[0217] In certain aspects, proprietary algorithms can be developed for use as CVD risk scores.

[0218] In some embodiments, the method for obtaining a CVD risk score may include a step for calculating a VECTRA-CVD score.

[0219] For example, the VECTRA-CVD score can be calculated according to Formula III: TIFF2024161429000004.tif70128 where Adjusted MBDA is the biomarker / clinical score described above that combines the MBDA score with the clinical parameters age and sex, plus additional LEP adjustment terms. Coefficients C1-C9 can be determined by the multi-step statistical model development and analysis interpretation functions described herein.

[0220] For "smoking", smoking is equal to 1 if the patient is designated as a smoker and 0 otherwise.

[0221] “Diabetes” is 1 if the patient has diabetes and 0 if not.

[0222] "High Blood Pressure" is 1 if the patient has high blood pressure and 0 if not.

[0223] For “history of CVD,” the score was 1 if the patient had a history of CVD and 0 if not.

[0224] In certain embodiments, in calculating the VECTRA-CVD score, leptin, TNFR1 and MMP3 refer to the serum concentrations of these biomarkers measured in ng / mL, while in calculating the Adjusted MBDA score from MBDA 2.0, leptin concentrations are measured in pg / mL.

[0225] In some embodiments, the coefficients C1-C9 of the VECTRA CVD score can be in the ranges shown in Table 1.

[0226] (Table 1) Range of coefficients C1 to C9 TIFF2024161429000005.tif73153

[0227] In some embodiments, the internal coefficient of tanh (adjusted VECTRA denominator) may range from 32.92229 to 33.23917, preferably 33.08073 ± 0.16.

[0228] In some embodiments, the internal coefficient of tanh (adjusted VECTRA denominator) may be in the range of 32.9223 to 33.2392, preferably 33.0807 ± 0.15.

[0229] In some embodiments, the internal coefficient of tanh (adjusted VECTRA denominator) may range from 32.922 to 33.239, preferably 33.081±0.15.

[0230] In some embodiments, the internal coefficient of tanh (adjusted VECTRA denominator) may range from 32.92 to 33.24, preferably 33.08±0.15.

[0231] In some embodiments, the internal coefficient of tanh (adjusted VECTRA denominator) may be in the range of 32.9 to 33.2, preferably 33.1±0.2.

[0232] In some embodiments, C1 can be 0.80, or 0.90, or 1.00, or 1.10, or 1.20, or 1.30, or 1.40, or 1.50, or 1.60, or 1.70, or 1.80, or 1.90, or 2.00, or 2.10, or 2.20, or 2.30, or 2.41.

[0233] In some embodiments, C1 can range from 0.805184 to 2.409979, preferably 1.607582±0.8.

[0234] In some embodiments, C1 can be 1.61±0.80, or 1.607±0.802, or 1.6076±0.8024.

[0235] In some embodiments, C1 can be 0.8 to 2.4, preferably 1.6±0.8.

[0236] In some embodiments, C1 can be between 0.80 and 2.41, preferably 1.61±0.8.

[0237] In some embodiments, C1 can be between 0.805 and 2.410, preferably 1.607±0.8.

[0238] In some embodiments, C1 can be between 0.8052 and 2.4100, preferably 1.6076±0.8.

[0239] In some embodiments, C2 can be −0.10, or −0.11, or −0.12, or −0.13, or −0.14, or −0.15, or −0.16, or −0.17, or −0.18, or −0.19, or −0.20, or −0.21, or −0.22, or −0.23, or −0.24.

[0240] In some embodiments, C2 is −0.17±0.07, or −0.171±0.070, or It can be −0.1711±0.0703.

[0241] In some embodiments, C2 can be −0.24 to −0.10, preferably −0.17±0.07.

[0242] In some embodiments, C2 can be between −0.241 and −0.101, preferably −0.171±0.07.

[0243] In some embodiments, C2 can be between −0.2414 and −0.1008, preferably −0.1711±0.07.

[0244] In some embodiments, C3 can be 0.36 to 0.78, or 0.359 to 0.786, or 0.3592 to 0.7857.

[0245] In some embodiments, C3 can be 0.57±0.21, or 0.572±0.213, or 0.5724±0.2133.

[0246] In some embodiments, C3 can be 0.36 to 0.78, preferably 0.57±0.2.

[0247] In some embodiments, C3 can be between 0.359 and 0.786, preferably 0.572±0.2.

[0248] In some embodiments, C3 can be between 0.3592 and 0.7857, preferably 0.5724±0.2.

[0249] In some embodiments, C4 can be 0.03 to 0.26, or 0.030 to 0.260, or 0.0304 to 0.2602.

[0250] In some embodiments, C4 can be 0.14±0.11, or 0.145±0.115, or 0.1453±0.1148.

[0251] In some embodiments, C4 can be between 0.03 and 0.26, preferably 0.14±0.1.

[0252] In some embodiments, C4 can be 0.030 to 0.260, preferably 0.145±0.1.

[0253] In some embodiments, C4 can be between 0.0305 and 0.2602, preferably 0.1453±0.1.

[0254] In some embodiments, C5 can be 0.02 to 0.04, or 0.021 to 0.041, or 0.0218 to 0.0411.

[0255] In some embodiments, C5 can be 0.03±0.01, or 0.031±0.010, or 0.0314±0.0097.

[0256] In some embodiments, C5 can be 0.02 to 0.04, preferably 0.03±0.01.

[0257] In some embodiments, C5 can be 0.022 to 0.041, preferably 0.031±0.01.

[0258] In some embodiments, C5 can be 0.0218 to 0.0411, preferably 0.0314±0.01.

[0259] In some embodiments, C6 can be 0.08 to 0.45, or 0.087 to 0.451, or 0.0874 to 0.4508.

[0260] In some embodiments, C6 can be 0.26±0.18, or 0.269±0.182, or 0.2691±0.1817.

[0261] In some embodiments, C6 can be 0.08 to 0.45, preferably 0.26±0.2.

[0262] In some embodiments, C6 can be between 0.087 and 0.451, preferably 0.269±0.2.

[0263] In some embodiments, C6 can be 0.0874 to 0.4508, preferably 0.2691±0.2.

[0264] In some embodiments, C7 can be 0.10 to 0.44, or 0.108 to 0.438, or 0.1078 to 0.4386.

[0265] In some embodiments, C7 can be 0.27±0.16, or 0.273±0.165, or 0.2732±0.1654.

[0266] In some embodiments, C7 can be between 0.11 and 0.44, preferably 0.27±0.2.

[0267] In some embodiments, C7 can be between 0.108 and 0.438, preferably 0.273±0.2.

[0268] In some embodiments, C7 can be between 0.1078 and 0.4386, preferably 0.2732±0.2.

[0269] In some embodiments, C8 can be 0.01 to 0.53, or 0.005 to 0.534, or 0.0050 to 0.5337.

[0270] In some embodiments, C8 can be 0.27±0.26, or 0.269±0.264, or 0.2694±0.2643.

[0271] In some embodiments, C8 can be 0.005 to 0.53, preferably 0.27±0.3.

[0272] In some embodiments, C8 can be between 0.005 and 0.533, preferably 0.269±0.3.

[0273] In some embodiments, C8 can be between 0.0050 and 0.5337, preferably 0.2694±0.3.

[0274] In some embodiments, C9 can be 0.17 to 0.51, or 0.167 to 0.508, or 0.1671 to 0.5084.

[0275] In some embodiments, C9 can be 0.34±0.17, or 0.338±0.167, or 0.3378±0.1671.

[0276] In some embodiments, C9 can be between 0.17 and 0.51, preferably 0.34±0.2.

[0277] In some embodiments, C9 can be 0.167 to 0.508, preferably 0.338±0.2.

[0278] In some embodiments, C9 can be between 0.1671 and 0.5085, preferably 0.3378±0.2.

[0279] In certain embodiments, when an individual marker condition is missing, the missing condition can be replaced with the average value obtained from the training data set to calculate the VECTRA CVD risk score. For example, if "smoking" data is not available, the term "+C6 x smoking" can be replaced with the average value obtained from the training data set.

[0280] In some embodiments, the final VECTRA-CVD score for a RA patient can be calculated according to Formula IV: TIFF2024161429000006.tif69128

[0281] In a further embodiment, the VECTRA-CVD score can be calculated according to Formula V: TIFF2024161429000007.tif71128

[0282] In some embodiments, the CVD risk score predictor test algorithm may include converting the VECTRA-CVD score to a percent risk.

[0283] In a further embodiment, the VECTRA-CVD score can be converted to a percent risk CVD risk score using formula VI: TIFF2024161429000008.tif18128 where A reflects the baseline risk, which is the probability of not experiencing a CVD event within 3 years if the VECTRA-CVD score is 0, and B is a calibration constant applied to the training dataset.

[0284] The interpretation function can provide an algorithm for a CVD score that includes a hyperbolic tangent or exponential function of the biomarker score. The interpretation function can provide an algorithm for a CVD score that is a VECTRA-CVD score.

[0285] An example of an interpretation function includes equation VI:

[0286] Baseline survival will be estimated in the validation dataset from a Cox proportional hazards regression model with VECTRA-CVD score as the only predictor.

[0287] For example, in certain embodiments, A, which is the baseline survival rate and the probability of being free of a CVD event within 3 years given a VECTRA-CVD score of 0, is 0.9996, and B, which is the adjustment from the training estimated coefficients to the validation estimated risk, is 1.0646.

[0288] In a further embodiment, A, which is the baseline survival rate and the probability of being free of a CVD event within 3 years given a VECTRA-CVD score of 0, is 0.99963462142575399, and B, which is the adjustment from the training estimated coefficients to the validation estimated risk, is 1.064597.

[0289] In a further embodiment, the ranges of quantities A and B in percent risk calculated from the VECTRA-CVD score are shown in Table 2.

[0290] Table 2. Range of quantities A and B in percent risk calculated from VECTRA CVD score TIFF2024161429000009.tif21166

[0291] In a further embodiment, the value of A on the ln(-ln(A)) scale can be -7.914394, with a range of -8.699876 to -7.128912.

[0292] In some embodiments, A can be between 0.9992 and 0.9998, or between 0.99920 and 0.99983, or between 0.999198 and 0.999833, or between 0.9991987 and 0.9998334.

[0293] In some embodiments, A can be 0.9996±0.0003, or 0.99963±0.0003, or 0.999635±0.0003, or 0.9996346±0.0003.

[0294] In some embodiments, A can be between 0.9992 and 0.9998, preferably 0.9996±0.0003.

[0295] In some embodiments, A can be between 0.99920 and 0.99983, preferably 0.99963±0.0003.

[0296] In some embodiments, A can be between 0.999199 and 0.999833, preferably 0.999635±0.0003.

[0297] In some embodiments, A can be between 0.9991987 and 0.9998334, preferably 0.9996346±0.0003.

[0298] In some embodiments, B can be between 0.90 and 1.23, or between 0.903 and 1.226, or between 0.9028 and 1.2264, or between 0.90281 and 1.22638, or between 0.902812 and 1.226382.

[0299] In some embodiments, B can be 1.06±0.16, or 1.064±0.162, or 1.0646±0.1618, or 1.06460±0.16178, or 1.064597±0.161785.

[0300] In some embodiments, B can be between 0.90 and 1.23, preferably 1.06±0.2.

[0301] In some embodiments, B can be between 0.903 and 1.226, preferably 1.064±0.2.

[0302] In some embodiments, B can be between 0.9028 and 1.2264, preferably 1.0646±0.2.

[0303] For example, for an exemplary patient with an adjusted VECTRA score of 46, age 70, leptin level 3.7 ng / mL, MMP3 level 21 ng / mL, TNFR1 level 2.8 ng / mL, who is non-diabetic, a smoker, has hypertension, and a history of CVD, the CVD risk score is shown in Formula VII: TIFF2024161429000010.tif84128

[0304] The percent risk for this exemplary patient as a CVD 3-year risk % is shown in Formula VIII: TIFF2024161429000011.tif21128

[0305] The present invention further contemplates a method for assessing and treating CVD risk in RA by clinically validating the predictive ability of the CVD term risk % value of the present disclosure. The survival rate of RA patients can be used to validate the three or four CVD risk group thresholds for the predictive CVD term risk % value of the present invention.

[0306] In some embodiments, the thresholds can be low, medium, and high CVD risk. In further embodiments, the thresholds can be low, borderline, medium, and high CVD risk.

[0307] In a further aspect, the method for evaluating and treating CVD risk in RA by clinically validating the predictive ability of CVD duration risk% value can include a wide range of risk periods.In certain embodiments, the period of CVD duration risk% can be 1-20 years.In certain embodiments, the period of CVD duration risk% can be CVD 1-year risk%, or CVD 2-year risk%, or CVD 3-year risk%, or CVD 4-year risk%, or CVD 5-year risk%, or CVD 6-year risk%, or CVD 7-year risk%, or CVD 8-year risk%, or CVD 9-year risk%, or CVD 10-year risk%.In certain embodiments, the period of CVD duration risk% can be any period based on, for example, hours, days, months, or years.

[0308] The method disclosed herein can expand the patient population that is included in the treatment. In some embodiments, the present invention provides CVD 3-year risk % values ​​with surprisingly improved accuracy, which allows patients to be reclassified as having a higher risk than expected. Reclassified patients who would not have been treated otherwise can be treated. The patient population that is included in the treatment can be expanded by the method of the present invention that accurately assesses the risk of CVD in RA. The type of CVD or RA treatment applied to the patient population can be changed because the method of the present invention that accurately assesses the risk of CVD in RA reclassifies the patient risk.

[0309] In some embodiments, the risk categories that may serve as thresholds for the CVD 3-year % risk of the present invention can be validated from actual incidence of clinical outcomes in patients.

[0310] In a further aspect, the risk categories, which may be thresholds for the CVD risk % of the present invention, may take into account the 2019 ACC / AHA guidelines for primary prevention of cardiovascular disease.

[0311] In certain embodiments, the risk categories that may be thresholds for the % CVD risk of the present invention may take into account the 10-year ACC / AHA thresholds of 5% (±0.1%), 7.5% (±0.1%), and 20% (±0.1%) risk. The thresholds may be selected based on cumulative risk.

[0312] The thresholds can be described as low risk, borderline risk, medium risk, and high risk. In certain embodiments, low risk and borderline risk can be combined.

[0313] In some embodiments, the CVD 3-year risk % of the present invention can be used to reclassify patients based on CVD risk in RA.

[0314] In the three year time frame example, a threshold can be selected for categorization.

[0315] In certain embodiments, the thresholds can be low risk (cumulative risk 0-1.8% or less), medium risk (1.8-5.2%), and high risk (5.2% or more).

[0316] In certain embodiments, the thresholds may correspond to the 10-year ACC / AHA thresholds of 7.5% (+-0.1%) and 20% (+-0.1%) risk.

[0317] In additional embodiments, the threshold value can be selected according to any one of Tables 3-5.

[0318] (Table 3) CVD risk thresholds TIFF2024161429000012.tif31128

[0319] (Table 4) CVD risk thresholds TIFF2024161429000013.tif38128

[0320] Table 5: CVD risk thresholds TIFF2024161429000014.tif31128

[0321] The amount of one or more biomarkers of the present teachings can be indicated as a value. The value can be one or more numerical values ​​resulting from the evaluation of a sample, for example, by measuring the level of one or more biomarkers in the sample by an assay performed in a laboratory, or can be derived from a data set obtained from a provider such as a laboratory, or from a data set stored on a server. Biomarker levels can be measured using any of several techniques known in the art. The present teachings encompass such techniques and further include fasting and / or time-based sampling procedures for all subjects to measure biomarkers.

[0322] "Biomarker", "biomarkers", "marker" or "markers" in the context of this disclosure include, but are not limited to, cytokines, chemokines, growth factors, proteins, peptides, nucleic acids, oligonucleotides, and metabolites, as well as their associated metabolites, mutants, isoforms, variants, polymorphisms, modifications, fragments, subunits, degradation products, elements, and other analytes or measurements derived from a sample. Biomarkers may also include mutant proteins, mutant nucleic acids, copy number variations, and / or transcriptional variants. Biomarkers also include non-blood borne and non-analyte physiological markers of health status, and / or other factors or markers that are not measured from a sample (e.g., a biological sample such as a bodily fluid), such as clinical parameters and traditional factors for clinical evaluation. Biomarkers may also include any index that is mathematically calculated and / or created. Biomarkers may also include combinations of any one or more of the aforementioned measurements, including time trends and differences. Where the biomarkers of certain embodiments of the present teachings are proteins, the gene abbreviations and names used herein should be understood to refer to the protein products of these genes, which are intended to include any protein isoforms of these genes, whether or not such isoform sequences are specifically described herein. Where the biomarkers are nucleic acids, the gene abbreviations and names used herein should be understood to refer to the nucleic acids (DNA or RNA) of these genes, which are intended to include any transcript variants of these genes, whether or not such transcript variants are specifically described herein.

[0323] The term "cytokine" in the present teachings refers to any substance secreted by certain cells, which may be of the immune system, that transmits signals between cells and thus affects other cells. The term "cytokine" encompasses "growth factors." "Chemokines" are also cytokines. They are a subset of cytokines that can induce chemotaxis in cells. Therefore, they are also known as "chemotactic cytokines."

[0324] "Measuring" or "measuring" as well as "detecting" or "detection" in the context of this disclosure refer to determining the presence, absence, amount, content or effective amount of a substance in a clinical or subject-derived sample (including the concentration level of such a substance), or assessing the value or categorization of a subject's clinical parameter.

[0325] As used herein, a "multiplex assay" refers to an assay that simultaneously measures multiple analytes, eg, protein analytes, in a single run or cycle of the assay.

[0326] "Quantitative dataset" or "quantitative data" as used in the present teachings refers to data obtained, for example, from detection and composite measurement of the expression of multiple biomarkers (i.e., two or more) in a subject sample. Quantitative datasets can be used to generate scores for identifying, monitoring and treating disease states, and characterize the biological state of a subject. Different biomarkers can be detected depending on the disease state or physiological state of interest.

[0327] The term "analyte" in the context of this disclosure can refer to any substance that is measured and can include biomarkers, markers, nucleic acids, electrolytes, metabolites, proteins, sugars, carbohydrates, fats, lipids, cytokines, chemokines, growth factors, proteins, peptides, nucleic acids, oligonucleotides, metabolites, mutants, variants, polymorphisms, modifications, fragments, subunits, degradation products, and other elements. For brevity, rather than using standard protein abbreviations, standard gene abbreviations may be used throughout to refer to genes as well as gene products / proteins. For example, APOA1 as used herein can refer to the gene APOA1 and the protein ApoAI. Generally, analytes and abbreviations herein have the hyphen omitted (IL-6=IL6).

[0328] "Analyzing" includes determining a value or set of values ​​associated with a sample by measuring the analyte level in the sample. "Analyzing" may further include comparing the level to the component level in a sample or set of samples from the same subject or another subject, including a reference level. The biomarkers of the present teachings can be analyzed by any of a variety of methods in the art. Some such methods include, but are not limited to, measuring serum protein or sugar or metabolite or other analyte levels, measuring enzyme activity, and measuring gene expression. Some techniques include immunoassays, mass spectrometry, and the like. "Immunoassay" as used herein refers to a biochemical assay that uses one or more antibodies to measure the presence or concentration of an analyte or biomarker in a biological sample.

[0329] The actual measurement of the level of the biomarker can be determined at the protein or nucleic acid level using any method known in the art. "Protein" detection includes detection of full-length proteins, mature proteins, preproteins, polypeptides, isoforms, mutants, variants, post-translationally modified proteins and variants thereof, and can be detected by any suitable method. The level of the biomarker can be determined at the protein level, for example, by measuring the serum levels of peptides encoded by the gene products described herein, or by measuring the enzymatic activity of these protein biomarkers. Such methods are well known in the art and include, for example, immunoassays based on antibodies to proteins encoded by genes, aptamers or molecular imprints. Any biological material can be used for the detection / quantification of the protein or its activity. Alternatively, a suitable method can be selected to determine the activity of the protein encoded by the biomarker gene by the activity of each protein analyzed. For biomarker proteins, polypeptides, isoforms, mutants, and variants thereof known to have enzymatic activity, the activity can be determined in vitro using enzymatic assays known in the art. Such assays include, but are not limited to, protease assays, kinase assays, phosphatase assays, reductase assays, among others. Modulation of the kinetics of enzyme activity can be determined by measuring the rate constant, KM, using known algorithms such as Hill plots, Michaelis-Menten equations, linear regression plots such as Lineweaver-Burk analysis, and Scatchard plots.

[0330] The term "antibody" refers to any immunoglobulin-like molecule that reversibly binds to another with the required selectivity. Thus, the term includes any such molecule that can selectively bind to a biomarker of the present teachings. The term includes immunoglobulin molecules that can bind to an epitope present on an antigen. The term includes complete immunoglobulin molecules, such as, for example, monoclonal and polyclonal antibodies, as well as antibody isotypes, recombinant antibodies, bispecific antibodies, humanized antibodies, chimeric antibodies, anti-idiopathic (anti-ID) antibodies, single chain antibodies, Fab fragments, F(ab') fragments, fusion protein antibody fragments, immunoglobulin fragments, F(ab') ... v Fragment, single strand F v Also intended to be encompassed are fragments and chimeras comprising immunoglobulin sequences, as well as any modifications of the foregoing that contain the required selective antigen recognition sites.

[0331] The sequence information provided by the public database entries of the biomarkers can be used to detect and measure the expression of the biomarkers using techniques well known to those of skill in the art. For example, the nucleic acid sequences in the sequence databases corresponding to the nucleic acids of the biomarkers can be used to construct primers and probes for detecting and / or measuring the biomarker nucleic acids. These probes can be used, for example, in Northern or Southern blot hybridization analysis, ribonuclease protection assays, and / or methods for quantitatively amplifying specific nucleic acid sequences. As another example, sequences from the sequence databases can be used to construct primers for specifically amplifying the biomarker sequences in amplification-based detection and quantification methods, such as, for example, reverse transcription-based polymerase chain reaction (RT-PCR) and PCR. When the changes in gene expression are related to gene amplification, nucleotide deletions, polymorphisms, post-translational modifications and / or mutations, sequence comparisons in the test and reference populations can be made by comparing the relative amounts of the examined DNA sequences in the test and reference populations.

[0332] As an example, gene expression can be determined using Northern hybridization analysis, using a probe that specifically recognizes one or more of these sequences. Alternatively, expression can be measured using RT-PCR. For example, polynucleotide primers specific to the differentially expressed biomarker mRNA sequences reverse transcribe the mRNA into DNA, which can then be amplified by PCR and visualized and quantified. Biomarker RNA can also be quantified using other target amplification methods, such as TMA, SDA, and NASBA, or signal amplification methods (e.g., bDNA). Ribonuclease protection assays can also be used to determine gene expression, using a probe that specifically recognizes one or more biomarker mRNA sequences.

[0333] Alternatively, biomarker protein and nucleic acid metabolites can be measured. The term "metabolite" includes any chemical or biochemical product of a metabolic process, such as any compound produced by processing, cleavage or consumption of a biological molecule (e.g., protein, nucleic acid, carbohydrate, or lipid). Metabolites can be detected by a variety of methods known to those skilled in the art, including refractive index spectroscopy (RI), ultraviolet spectroscopy (UV), fluorescence spectroscopy, radiochemical analysis, near infrared spectroscopy (near IR), nuclear magnetic resonance spectroscopy (NMR), light scattering analysis (LS), mass spectrometry, pyrolysis mass spectrometry, nephelometry, dispersive Raman spectroscopy, gas chromatography combined with mass spectrometry, liquid chromatography combined with mass spectrometry, matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) combined with mass spectrometry, ion spray spectrometry combined with mass spectrometry, capillary electrophoresis, NMR and IR detection. See, for example, WO 04 / 056456 and WO 04 / 088309. Each of these is incorporated herein by reference in its entirety. In this regard, other biomarker analytes can be measured using the detection methods described above or other methods known to those of skill in the art. For example, circulating calcium ions (Ca 2+) can be detected in samples using fluorescent dyes such as the Fluo series, Fura-2A, Rhod-2, among others. Other biomarker metabolites can be similarly detected using reagents specifically designed or tailored to detect such metabolites.

[0334] In some embodiments, the biomarkers are detected by contacting the subject sample with a reagent, forming a complex between the reagent and the analyte, and detecting the complex. Examples of "reagents" include, but are not limited to, nucleic acid primers and antibodies.

[0335] In some embodiments of the present teachings, an antibody binding assay is used to detect a biomarker. For example, a sample from a subject is contacted with an antibody reagent that binds a biomarker analyte, a reaction product (or complex) comprising the antibody reagent and the analyte is generated, and the presence (or absence) or amount of the complex is determined. The antibody reagent useful for detecting a biomarker analyte can be monoclonal, polyclonal, chimeric, recombinant, or a fragment of the above, as discussed in detail above, and the step of detecting the reaction product can be carried out in any suitable immunoassay. The sample from the subject is typically a biological fluid as described above, and can be a sample of the same biological fluid used to carry out the above method.

[0336] Immunoassays performed according to the present teachings can be homogeneous or heterogeneous. Immunoassays performed according to the present teachings can be multiplexed. In homogeneous assays, the immunological reaction can include a specific antibody (e.g., an anti-biomarker protein antibody), a labeled analyte, and a sample of interest. The label generates a signal, and the signal resulting from the label is modified directly or indirectly upon binding of the labeled analyte to the antibody. Both the immunological reaction of binding and the detection of the degree of binding can be performed in a homogeneous solution. Immunochemical labels that can be used include, but are not limited to, free radicals, radioisotopes, fluorescent dyes, enzymes, bacteriophages, and coenzymes. Immunoassays include competitive assays.

[0337] In a heterogeneous assay approach, the reagents can be the sample of interest, the antibody, and a reagent for generating a detectable signal. Samples as described above can be used. The antibody can be immobilized on a support, such as beads (such as protein A and protein G agarose beads), a plate or a slide, and contacted with a sample suspected of containing a biomarker in a liquid phase. The support is separated from the liquid phase, and either the support phase or the liquid phase is examined using a method for detecting a signal known in the art. The signal is related to the presence of the analyte in the sample. Methods for generating a detectable signal include, but are not limited to, the use of radioactive, fluorescent or enzymatic labels. For example, if the antigen to be detected contains a second binding site, the antibody that binds to that site can be conjugated to a detectable (signal generating) group and added to the liquid phase reaction solution before the separation step. The presence of the detectable group on the solid support indicates the presence of the biomarker in the test sample. Examples of suitable immunoassays include, but are not limited to, oligonucleotides, immunoblotting, immunoprecipitation, immunofluorescence, chemiluminescence, electrochemiluminescence (ECL), and / or enzyme-linked immunoassays (ELISA).

[0338] Those of skill in the art will be familiar with the many specific immunoassay formats and variations thereof that may be useful in carrying out the methods disclosed herein. See, e.g., E. Maggio, Enzyme-Immunoassay (1980), CRC Press, Inc., Boca Raton, FL. U.S. Patent No. 4,727,022 by C. Skold et al., entitled "Novel Methods for Modulating Ligand-Receptor Interactions and their Application"; U.S. Patent No. 4,659,678 by GC Forrest et al., entitled "Immunoassay of Antigens"; U.S. Patent No. 4,376,110 by GS David et al., entitled "Immunometric Assays Using Monoclonal Antibodies"; U.S. Patent No. 4,275,149 by D. Litman et al., entitled "Macromolecular Environment Control in Specific Receptor Assays"; U.S. Patent No. 4,233,402 by E. Maggio et al., entitled "Reagents and Method Employing Channeling"; and U.S. Patent No. 4,233,402 by R. Boguslaski et al., entitled "Heterogenous Specific Binding Assay Employing a Coenzyme as Label". See also U.S. Pat. No. 4,230,797 to al.

[0339] The antibodies can be conjugated to a solid support suitable for diagnostic assays (e.g., beads such as protein A or protein G agarose, microspheres formed from materials such as latex or polystyrene, plates, slides or wells) according to known techniques, such as passive binding. The antibodies described herein can also be conjugated to detectable labels or groups, such as radioactive labels (e.g., 35S, 125I, 131I), enzyme labels (e.g., horseradish peroxidase, alkaline phosphatase), and fluorescent labels (e.g., fluorescein, Alexa, green fluorescent protein, rhodamine), according to known techniques.

[0340] Antibodies can also be useful for detecting post-translational modifications of biomarkers. Examples of post-translational modifications include, but are not limited to, tyrosine phosphorylation, threonine phosphorylation, serine phosphorylation, citrullination and glycosylation (e.g., O-GlcNAc). Such antibodies specifically detect phosphorylated amino acids in one or more proteins of interest and can be used in immunoblotting, immunofluorescence, and ELISA assays as described herein. These antibodies are well known to those skilled in the art and are commercially available. Post-translational modifications can also be determined using metastable ions in reflector matrix-assisted laser desorption / ionization time-of-flight mass spectrometry (MALDI-TOF). See U.Wirth et al., Proteomics 2002,2(10):1445-1451.

[0341] The present invention can provide a method for recommending a treatment regimen, including weaning, tapering or stopping the treatment regimen.The method for recommending a treatment regimen can be based on determining the difference in expression of the biomarkers disclosed herein.The method for recommending a treatment regimen can be based on determining the CVD risk score of the present invention.

[0342] By measuring the scores derived from the expression levels of the biomarkers disclosed herein over a period of time, clinicians can obtain a dynamic picture of the biological state of a subject. Thus, these aspects of the present teachings provide subject-specific biological information that will be beneficial for treatment decisions and facilitate monitoring of treatment response, leading to faster optimized treatment, better disease control, and an increased proportion of subjects achieving remission.

[0343] A "biologic" or "biotherapeutic" or "biopharmaceutical" may be a pharmaceutical therapy product manufactured or extracted from biological material. Biologics may include vaccines, blood or blood components, allergenic substances, somatic cells, gene therapy, tissues, recombinant proteins, and live cells, and may be composed of sugars, proteins, nucleic acids, live cells or tissues, or combinations thereof. Examples of biologic drugs may include, but are not limited to, biological agents that target tumor necrosis factor (TNF)-alpha molecules and TNF inhibitors, such as infliximab, adalimumab, etanercept, and golimumab. Other classes of biologic drugs include IL1 inhibitors such as anakinra, T cell modulators such as abatacept, B cell modulators such as rituximab, and IL6 inhibitors such as tocilizumab.

[0344] The treatment strategy of CVD for patients with autoimmune disorders is confounded by the fact that some autoimmune disorders, such as RA, can be a classification given to a group of subjects with a diverse set of related symptoms that can flare or go into remission.This suggests that certain subtypes of RA are driven by specific cell types or cytokines.As a possible consequence, no single treatment has proven to be optimal for treatment.Given the increasing number of available treatment options, the need for individually tailored treatments, guided by immunological prognostic factors of treatment outcome, may be required.

[0345] The term "flare" as used herein may refer to a sudden and increasing severity of onset of symptoms and clinical symptoms including, but not limited to, increased SJCs, increased TJCs, increased serological markers of inflammation (e.g., CRP and ESR), decreased function of the subject (e.g., ability to perform basic daily activities), increased morning stiffness, and increased pain that typically leads to therapeutic intervention and potentially intensification of treatment.

[0346] In some embodiments, prediction of CVD risk in RA patients who can successfully wean off or stop treatment can be based on MBDA score.In some embodiments, the high MBDA score at baseline described herein can be an independent predictor of risk within a period of time after treatment is stopped.In some embodiments, the moderate MBDA score at baseline described herein can be an independent predictor of risk within a period of time after treatment is stopped.In some embodiments, the low MBDA score at baseline described herein can be an independent predictor of risk within a period of time after treatment is stopped or remission.

[0347] As used herein, a "therapeutic regimen," "therapy," or "treatment" includes all clinical management and interventions of a subject, whether biological, chemical, physical, or a combination thereof, intended to sustain, reverse, improve, or otherwise alter the subject's condition. These terms may be used interchangeably herein. Treatment includes, but is not limited to, administration of prophylactic or therapeutic compounds (including conventional DMARDs, biologic DMARDs, nonsteroidal anti-inflammatory drugs (NSAIDs) such as COX-2 selective inhibitors, and corticosteroids), exercise regimens, physical therapy, dietary modification and / or supplementation, bariatric surgical intervention, administration of pharmaceuticals and / or anti-inflammatory drugs (prescription or OTC), and any other treatment known in the art to be effective in preventing, delaying the onset, or ameliorating disease. A "response to treatment" includes the subject's response to any of the above treatments, whether biological, chemical, physical, or a combination of the foregoing. A "course of treatment" refers to the dosage, duration, extent, etc., of a particular treatment or treatment regimen. As used herein, an initial treatment regimen may be the first line of treatment.

[0348] DMARDs can be conventional or biologics.The examples of DMARDs that are generally considered to be conventional include, but are not limited to, MTX, azathioprine (AZA), bucillamine (BUC), chloroquine (CQ), cyclosporin (CSA, or cyclosporine, or cyclosporin), doxycycline (DOXY), hydroxychloroquine (HCQ), intramuscular gold (IM gold), leflunomide (LEF), levofloxacin (LEV), and sulfasalazine (SSZ).Other examples of conventional DMARDs include, but are not limited to, folinic acid, D-pencilamine, auranofin gold, aurothioglucose gold, thiomalate gold, cyclophosphamide, and chlorambucil. Examples of biologic DMARDs (biologic drugs) may include, but are not limited to, biological agents that target tumor necrosis factor (TNF)-alpha molecules, such as infliximab, adalimumab, etanercept, and golimumab. Other classes of biologic DMARDs include IL1 inhibitors such as anakinra, T cell modulators such as abatacept, B cell modulators such as rituximab, and IL6 inhibitors such as tocilizumab.

[0349] Treatment strategies for CVD in patients with autoimmune disorders may include one or more of the drugs in Table 6.

[0350] (Table 6) Generic names of drugs TIFF2024161429000015.tif222169

[0351] "Time point" as used herein refers to a way of describing time, which can be substantially described by a single point. A time point can also be described as a range of time in the smallest detectable unit. A time point can refer to a way of describing a state of an aspect of time, or a particular period of time. Such a time point or range can include units, for example, from seconds, minutes, to hours, or days.

[0352] In some embodiments, the level of one or more analyte biomarkers, or the level of a particular panel of analyte biomarkers, in a sample is compared to a reference standard ("reference standard" or "reference level" or "control") to direct treatment decisions. Expression levels of one or more biomarkers can be combined into a score that can represent risk.

[0353] A reference standard used in any of the embodiments disclosed herein may comprise the average, mean, or median levels of one or more analyte biomarkers in a control population, or the levels of a particular panel of analyte biomarkers.

[0354] Reference standard can further comprise previous time points for the same subject.For example, reference standard can comprise a first time point, and the level of one or more analyte biomarkers can be examined again at a second, third, fourth, fifth, sixth time point, etc.Any time point before a certain time point can be considered as reference standard.

[0355] A reference standard may further include a cut-off value or any other statistical attribute of a control population, or a standard deviation from a previous time point of the same subject, e.g., the mean level of one or more analyte biomarkers or the levels of a particular panel of analyte biomarkers.

[0356] In some embodiments, the control population may include healthy individuals or the same subjects prior to administration of any treatment.

[0357] The reference standard may essentially reflect the clinical training and / or validation data used in the methods of the present disclosure.

[0358] In some embodiments, a score may be obtained from a reference time point, and a different score may be obtained from a later time point. The initial time point may be when an initial treatment regimen is initiated. The initial time point may also be when an initial immunoassay is performed. The time point may be hours, days, months, years, etc. In some embodiments, the time point is 1 month. In some embodiments, the time point is 2 months. In some embodiments, the time point is 3 months. In some embodiments, the time point is 4 months. In some embodiments, the time point is 5 months. In some embodiments, the time point is 6 months. In some embodiments, the time point is 7 months. In some embodiments, the time point is 8 months. In some embodiments, the time point is 9 months. In some embodiments, the time point is 10 months. In some embodiments, the time point is 11 months. In some embodiments, the time point is 12 months. In some embodiments, the time point is 2 years. In some embodiments, the time point is 3 years. In some embodiments, the time point is 4 years. In some embodiments, the time point is 5 years. In some embodiments, the time point is 10 years.

[0359] The difference in score can be interpreted as a reduction in risk. For example, a lower score can indicate a lower level of risk. In this situation, the second score having a lower score than the reference score or the first score means that the risk of the subject is reduced (improved) between the first period and the second period. Alternatively, a higher score can indicate a lower level of risk. In this situation, the second score having a higher score than the reference score or the first score also means that the risk of the subject is improved between the first period and the second period.

[0360] The difference in score can also be interpreted as an increase in risk. For example, a lower score can indicate a higher level of risk. In this situation, the second score having a lower score than the reference score or the first score means that the risk of the subject is increased (worsened) between the first period and the second period. Alternatively, a higher score can indicate a higher level of risk. In this situation, the second score having a higher score than the reference score or the first score also means that the risk of the subject is worsened between the first period and the second period.

[0361] The difference can be variable. For example, if the difference in score is interpreted as a reduction in risk, a large difference can mean a greater reduction in risk than a lower or moderate difference. Alternatively, if the difference in score is interpreted as an increase in risk, a large difference can mean a greater increase in risk than a lower or moderate difference.

[0362] In some embodiments, the patient may be treated more aggressively or less aggressively than the reference therapy based on the difference in scores. The reference therapy is any therapy that is the standard of care for treatment. Standards of care may vary over time and geography, and those skilled in the art can easily determine the appropriate standard of care by referring to the relevant medical literature.

[0363] In further aspects, treatment that is more aggressive than the standard of care includes initiating treatment earlier than the standard of care. In some aspects, treatment that is more aggressive than the standard of care includes administering additional treatments relative to the standard of care. In some aspects, treatment that is more aggressive than the standard of care includes administering treatment on an accelerated schedule compared to the standard of care. In some aspects, treatment that is more aggressive than the standard of care includes administering additional treatments not required by the standard of care.

[0364] In further aspects, treating less aggressively than the standard of care includes slowing treatment compared to the standard of care. In some aspects, treating less aggressively than the standard of care includes administering less treatment compared to the standard of care. In some aspects, treating less aggressively than the standard of care includes administering treatment on a slowed down schedule compared to the standard of care. In some aspects, treating less aggressively than the standard of care includes not administering treatment.

[0365] In some embodiments, the professional may discontinue the treatment regimen if the score is low, hi certain embodiments, the professional may not change the treatment regimen if the score is high.

[0366] In one embodiment, the professional adjusts the treatment based on a comparison between the different scores or based on the initial prediction score. In one embodiment, the professional adjusts the treatment by selecting and administering different drugs. In one embodiment, the professional adjusts the treatment by selecting and administering different combinations of drugs.

[0367] In one aspect, the professional adjusts the treatment by adjusting drug dosages. In one aspect, the professional adjusts the treatment by adjusting administration schedules. In one aspect, the professional adjusts the treatment by adjusting duration of treatment. In one aspect, the professional adjusts the treatment by selecting and administering a combination of different drugs and adjusting drug dosages.

[0368] In one aspect, the professional tailors the treatment by selecting and administering different drug combinations and adjusting the administration schedule. In one aspect, the professional tailors the treatment by selecting and administering different drug combinations and adjusting the duration of treatment. In one aspect, the professional tailors the treatment by adjusting drug dosages and administration schedules. In one aspect, the professional tailors the treatment by adjusting drug dosages and adjusting the duration of treatment.

[0369] In one aspect, the professional adjusts the treatment by adjusting the administration schedule and adjusting the duration of treatment. In one aspect, the professional adjusts the treatment by selecting and administering a different drug, adjusting the drug dosage, and adjusting the administration schedule. In one aspect, the professional adjusts the treatment by selecting and administering a different drug, adjusting the drug dosage, and adjusting the duration of treatment.

[0370] In one aspect, the professional adjusts the treatment by selecting and administering different drugs, adjusting the administration schedule, and adjusting the duration of treatment. In one aspect, the professional adjusts the treatment by adjusting drug dosages, adjusting the administration schedule, and adjusting the duration of treatment. In one aspect, the professional adjusts the treatment by selecting and administering different drugs, adjusting drug dosages, adjusting the administration schedule, and adjusting the duration of treatment.

[0371] In one aspect, a more aggressive treatment does not include a change in treatment regimen. In one aspect, a more aggressive treatment includes a delay in treatment. In one aspect, a more aggressive treatment includes the selection and administration of a less potent drug. In one aspect, a more aggressive treatment includes a reduction in the frequency of treatment. In one aspect, a more aggressive treatment includes a reduction in the duration of treatment.

[0372] In one embodiment, a more aggressive treatment involves selecting and administering a less potent drug and reducing the drug dosage. In one embodiment, a more aggressive treatment involves selecting and administering a less potent drug and slowing down the administration schedule. In one embodiment, a more aggressive treatment involves selecting and administering a less potent drug and shortening the duration of treatment.

[0373] In one embodiment, a more aggressive treatment includes reducing the drug dosage and slowing down the administration schedule. In one embodiment, a more aggressive treatment includes reducing the drug dosage and shortening the treatment period. In one embodiment, a more aggressive treatment includes slowing down the administration schedule and shortening the treatment period.

[0374] In one embodiment, the more aggressive treatment includes selecting and administering a less potent drug, reducing the drug dosage, and slowing down the administration schedule. In one embodiment, the more aggressive treatment includes selecting and administering a less potent drug, reducing the drug dosage, and shortening the duration of treatment. In one embodiment, the more aggressive treatment includes selecting and administering a less potent drug, slowing down the administration schedule, and shortening the duration of treatment. In one embodiment, the more aggressive treatment includes reducing the drug dosage, slowing down the administration schedule, and shortening the duration of treatment. In one embodiment, the more aggressive treatment includes selecting and administering a less potent drug, reducing the drug dosage, slowing down the administration schedule, and shortening the duration of treatment. In some embodiments, the more aggressive treatment includes administering only non-drug based treatments.

[0375] In another aspect of the present specification, the treatment includes a more aggressive treatment than the reference treatment. In one embodiment, the more aggressive treatment includes extending the treatment period. In one embodiment, the more aggressive treatment includes increasing the number of treatments. In one embodiment, the more aggressive treatment includes selecting and administering a more potent drug and increasing the drug dosage.

[0376] In one aspect, more aggressive treatment includes selecting and administering a more potent drug and accelerating the administration schedule. In one aspect, more aggressive treatment includes selecting and administering a more potent drug and extending the treatment period. In one aspect, more aggressive treatment includes increasing the drug dosage and accelerating the administration schedule. In one aspect, more aggressive treatment includes increasing the drug dosage and extending the treatment period. In one aspect, more aggressive treatment includes accelerating the administration schedule and extending the treatment period.

[0377] In one aspect, the more aggressive therapy includes selecting and administering a more potent drug, increasing the drug dosage, and accelerating the administration schedule. In one aspect, the more aggressive therapy includes selecting and administering a more potent drug, increasing the drug dosage, and extending the treatment period. In one aspect, the more aggressive therapy includes selecting and administering a more potent drug, accelerating the administration schedule, and extending the treatment period. In one aspect, the more aggressive therapy includes increasing the drug dosage, accelerating the administration schedule, and extending the treatment period. In one aspect, the more aggressive therapy includes selecting and administering a more potent drug, increasing the drug dosage, accelerating the administration schedule, and extending the treatment period. In some aspects, the more aggressive therapy includes administering a combination of drug-based therapies, non-drug-based therapies, or a combination of classes of drug-based therapies.

[0378] In some embodiments of the present disclosure, the MBDA score is adjusted to the population, endpoint or clinical evaluation, and / or intended use.For example, the MBDA score can be used to evaluate subjects for primary prevention and diagnosis, and secondary prevention and management.In primary evaluation, the MBDA score can be used to predict and risk stratify future conditions or disease sequelae, diagnose inflammatory disease and CVD risk, prognose disease activity and rate of change, and direct future diagnostic and treatment regimens.In secondary prevention and clinical management, the MBDA score can be used for prognosis and risk stratification.The MBDA score can be used to support clinical decisions such as deciding whether to postpone intervention or treatment, recommend preventive testing of at-risk patients, recommend increased visits, recommend increased testing, and recommend intervention.The MBDA score can also be useful for selecting treatment, determining response to treatment, adjusting and administering treatment, monitoring ongoing treatment efficiency, monitoring treatment withdrawal, and directing changes in treatment regimens.

[0379] In some embodiments of the present teachings, MBDA score can be used to aid in the diagnosis of inflammatory disease and prediction of CVD risk, and to determine the severity of inflammatory disease.MBDA score can also be used to determine the future state of intervention, for example, in RA, to determine the prognosis of future joint erosion with or without treatment, or CVD risk with or without treatment.Certain embodiments of the present teachings can be tailored to specific treatments or combinations of treatments.

[0380] Clinical variables that can be used to adjust the MBDA score include, for example, gender / sex, smoking status, age, race / ethnicity, disease duration, diastolic and systolic blood pressure, resting heart rate, height, weight, adiposity, body mass index, serum leptin, family history, CCP status (i.e., whether the subject is positive or negative for anti-CCP antibodies), CCP titer, RF status, RF titer, ESR, CRP titer, menopausal status, and whether smoker / non-smoker.

[0381] The term "clinical variable" or "clinical parameter" in the context of this disclosure encompasses all measures of a subject's health or physiological condition. Clinical parameters can be used to derive a clinical assessment of a subject's disease activity. Clinical parameters can include, but are not limited to, treatment regimen (including but not limited to DMARDs, whether conventional or biologic, steroids, etc.), TJC, SJC, morning stiffness, arthritis of three or more joint regions, arthritis of the wrist, symmetric arthritis, rheumatoid nodules, radiographic changes and other imaging, gender / sex, smoking status, age, race / ethnicity, disease duration, diastolic and systolic blood pressure, resting heart rate, height, weight, adiposity, body mass index, serum leptin, family history, CCP status (i.e., whether the subject is positive or negative for anti-CCP antibodies), CCP titer, RF status, RF titer, ESR, CRP titer, menopausal status, and whether smoker / non-smoker.

[0382] "Clinical assessment" and "clinical parameter" are not mutually exclusive terms. There may be overlap in the members of the two categories. For example, CRP concentration can be used as a clinical assessment of disease activity. Or, it can be used as a measure of the subject's health status and thus serve as a clinical parameter.

[0383] "Clinical assessment" or "clinical data point" or "clinical endpoint" in the context of the present teachings can refer to a measure of disease activity or severity. Clinical assessment can include a score, value, or set of values ​​that can be obtained from the evaluation of a sample (or a population of samples) from one or more subjects under determined conditions. Clinical assessment can also be a questionnaire that is completed by the subject. Clinical assessment can also be predicted by biomarkers and / or other parameters. Clinical assessments of RA may include, by way of example and without limitation, DAS (as defined herein), DAS28, DAS28-ESR, DAS28-CRP, Health Assessment Questionnaire (HAQ), modified HAQ (mHAQ), Multidimensional HAQ (MDHAQ), visual analog scale (VAS), Physician Global Assessment VAS, Patient Global Assessment VAS, Pain VAS, Fatigue VAS, Overall VAS, Sleep VAS, Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Routine Assessment of Patient Index Data (RAPID), RAPID3, RAPID4, RAPID5, American College of Rheumatology (ACR), ACR20, ACR50, ACR70, SF-36 (a well-validated measure of general health status), RA MRI score (RAMRIS; or RA MRI Scoring System), total Sharp score (TSS), van der Heijde-modified TSS, van der Heijde-modified One skilled in the art will recognize that the clinical outcomes may include one or more of the following: Sharp score (or Sharp-van der Heijde score (SHS)), Larsen score, TJC, swollen joint count (SJC), CRP titer (or level) and erythrocyte sedimentation rate (ESR).

[0384] "DAS" refers to the Disease Activity Score, which is a measure of the activity of RA in a subject, and is well known to those skilled in the art. See D. van der Heijde et al., Ann. Rheum. Dis. 1990, 49(11):916-920. "DAS" as used herein refers to this particular Disease Activity Score. "DAS28" includes the assessment of 28 specific joints. It may be a current standard that is well recognized in research and clinical practice. Since DAS28 may be a well recognized standard, it may be called "DAS". "DAS" may refer to a calculation based on 66 / 68 or 44 joint counts, but unless otherwise specified, "DAS" herein encompasses DAS28. Unless otherwise specified herein, the term "DAS28" as used in the present teachings may refer to DAS28-ESR or DAS28-CRP obtained by any of the four formulas above. Alternatively, DAS28 may refer to another reliable DAS28 formula that may be known in the art.

[0385] DAS28 can be calculated for RA subjects according to the criteria as outlined in the das-score.nl website, maintained by the Department of Rheumatology, University Medical Centre, Nijhemen, The Netherlands. The number of swollen joints, or the number of swollen joints out of a total of 28 (SJC28), and the number of tender joints, or the number of tender joints out of a total of 28 (TJC28) are assessed in each subject. In some DAS28 calculations, the subject's overall health (GH) is also a factor and can be measured on a 100 mm visual analogue scale (VAS). GH can also be referred to herein as PG or PGA, for "patient global health assessment" (or simply "patient global assessment"). "Patient Global Health Assessment VAS" is then GH measured on a visual analogue scale.

[0386] "DAS28-CRP" (or "DAS28CRP") is a DAS28 assessment calculated using CRP instead of ESR (see below). CRP is produced in the liver. Normally, there is little or no CRP circulating in an individual's serum. Since CRP is generally present in the body during episodes of acute inflammation or infection, an elevated or increased amount of CRP in serum can be associated with acute infection or inflammation. Serum levels of CRP above 1 mg / dL are usually considered high. Most inflammation and infections result in CRP levels above 10 mg / dL. The amount of CRP in a subject's serum can be quantified, for example, using the DSL-10-42100 ACTIVE® US C-Reactive Protein Enzyme-Linked Immunosorbent Assay (ELISA) developed by Diagnostics Systems Laboratories, Inc. (Webster, TX). CRP production is associated with the radiological progression of RA. See M. Van Leeuwen et al., Br. J. Rheum. 1993, 32(suppl.):9-13. Therefore, CRP is considered a suitable surrogate for ESR in measuring RA disease activity. See R. Mallya et al., J. Rheum. 1982, 9(2):224-228, and F. Wolfe, J. Rheum. 1997, 24:1477-1485.

[0387] DAS28-CRP, with or without the GH factor, can be calculated according to one of the following formulas, where "CRP" represents the amount of this protein in mg / L present in the serum of a subject, "sqrt" represents the square root, and "ln" represents the natural logarithm: (a) DAS28-CRP with GH (or DAS28-CRP4) = (0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(CRP+1)) + (0.014*GH) + 0.96; or (b) DAS28-CRP (or DAS28-CRP3) without GH = (0.56*sqrt(TJC28)+0.28*sqrt(SJC28)+0.36*ln(CRP+1))*1.10+1.15.

[0388] "DAS28-ESR" is the DAS28 assessment in which each subject's ESR (in mm / hour) is also measured. The DAS28-ESR can be calculated according to the following formula: (a) DAS28-ESR with GH (or DAS28-ESR4) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.70*ln(ESR) + 0.014*GH; or (b) DAS28-ESR without GH = 0.56*sqrt(TJC28)+0.28*sqrt(SJC28)+0.70*ln(ESR)*1.08+0.16.

[0389] FIG. 20 shows the biomarkers used to predict each DAS28-CRP component.

[0390] Tests for measuring risk according to various embodiments of the present teachings can be performed in various systems typically used to obtain test results, such as results from immunological or nucleic acid detection assays. Such systems may include modules that automate sample preparation, modules that automate tests such as measuring biomarker levels, modules that facilitate testing of multiple samples, and / or modules programmed to assay the same or different tests for each sample. In some embodiments, the test system includes one or more of a sample preparation module, a clinical chemistry module, and an immunoassay module on one platform. Test systems are typically designed to also include modules for collecting, storing, and tracking results, such as by connecting to and utilizing a database present on the hardware. Examples of these modules include physical and electronic data storage devices well known in the art, such as hard drives, flash memory, and magnetic tape. Test systems also generally include a module for reporting and / or visualizing results. Some examples of reporting modules include a visual display or graphical user interface, a link to a database, or a printer.

[0391] The term "computer" has its meaning commonly known in the art; that is, a machine for manipulating data according to a set of instructions. As used herein, the term "module" refers to computer program logic utilized to provide a specified function. Thus, a module may be implemented in hardware, firmware, and / or software. Aspects of the entities described herein may include separate and / or different modules than those described herein. In addition, functions attributed to a module may be performed by other or different modules in other aspects. Furthermore, this description may omit the term "module" for clarity and convenience.

[0392] In some embodiments, the present invention may include a system for determining a subject's CVD risk. In some embodiments, the system uses a module for applying a formula to an input including the measured levels of biomarkers in a panel and outputting a score, as described herein. In some embodiments, the measured biomarker levels are test results that serve as inputs to a computer programmed to apply the formula. The system may include other inputs in addition to or in combination with the biomarker results to derive an output score, such as one or more clinical parameters, such as treatment regimen, TJC, SJC, morning stiffness, arthritis in three or more joint areas, arthritis in the wrist, symmetric arthritis, rheumatoid nodules, radiographic changes and other imaging, gender / sex, age, race / ethnicity, disease duration, height, weight, body mass index, family history, CCP status, RF status, ESR, smoker / non-smoker, etc. In some embodiments, the system can apply a formula to the biomarker level input and then output a risk score that can be analyzed in conjunction with other inputs, such as other clinical parameters. In other embodiments, the system is designed to apply the formula to biomarker and non-biomarker inputs (such as clinical parameters) together and then report a composite output risk index.

[0393] Many test systems are currently available that can be used to practice various aspects of the present teachings. See, for example, the ARCHITECT Series of Integrated Immunochemistry Systems--an automated, high-throughput clinical chemistry analyzer (ARCHITECT is a registered trademark of Abbott Laboratories, Abbott Park, Ill. 60064). Wilson et al., "Clinical Chemistry Analyzer Sub-System Level Performance", American Association for Clinical Chemistry Annual Meeting, Chicago, Ill., Jul.23-27, 2006; and HJ Kisner, "Product development: the making of the Abbott ARCHITECT", Clin.Lab.Manage.Rev.1997 Nov.-Dec.,11(6):419-21;A.Ognibene et al., "A new modular chemiluminescence immunoassay analyzer evaluator", Clin.Chem.Lab.Med.2000 March,38(3):251-60;JW Park et al., "Three-year experience in using total laboratory automation system", Southeast Asian J.Trop.Med.Public Health 2002,33 Suppl 2:68-73;D. Pauli et al., “The Abbott Architect c8000: analytical performance and productivity characteristics of a new analyzer applied to general chemistry testing," Clin. Lab. 2005, 51(1-2):31-41.

[0394] Another testing system useful for embodiments of the present teachings is the VITROS system (VITROS, Johnson & Johnson Corp., New Brunswick, NJ), which is an instrument for chemical analysis for laboratories and clinics used to generate test results from blood and other bodily fluids. Another testing system is the DIMENSION system (DIMENSION, Dade Behring Inc., Deerfield Ill.), which is a system for analysis of bodily fluids that includes computer software and hardware for operating the analytical instrument and for analyzing data generated by the analytical instrument.

[0395] Tests required for various embodiments of the present teachings, e.g., measuring biomarker levels, can be performed by laboratories, such as those certified under the Clinical Laboratory Improvement Act (42 U.S.C. Section 263(a)), or any other Federal or State law, or any other country, state, or provincial law governing the operation of laboratories that analyze samples for clinical purposes. Such laboratories include, for example, Laboratory Corporation of America, 358 South Main Street, Burlington, NC 27215 (headquarters); Quest Diagnostics, 3 Giralda Farms, Madison, NJ 07940 (headquarters); and other reference laboratories and clinical chemistry laboratories.

[0396] Further embodiments of the present invention include biomarker detection reagents packaged together in the form of a kit for carrying out any of the assays of the present teachings. In certain embodiments, the kit includes oligonucleotides that specifically identify one or more biomarker nucleic acids based on homology and / or complementarity with the biomarker nucleic acids. The oligonucleotide sequences can correspond to fragments of the biomarker nucleic acids. For example, the length of the oligonucleotides can be more than 200, 200, 150, 100, 50, 25, 10, or less than 10 nucleotides. In other embodiments, the kit includes an antibody against a protein encoded by the biomarker nucleic acid. The kit of the present teachings can also include an aptamer. The kit can include nucleic acids or antibodies (either antibodies bound to a solid matrix or antibodies packaged separately from the reagents for binding to the matrix), control formulations (positive and / or negative), and / or detectable labels, such as, but not limited to, fluorescein, green fluorescent protein, rhodamine, cyanine dyes, Alexa dyes, luciferase, and radioactive labels, among others, in separate containers. The kit can include instructions, e.g., written, tape, VCR, or CD-ROM, for carrying out the assay, optionally including instructions for generating an MBDA score. The assay can be, for example, in the form of a Northern hybridization or sandwich ELISA, as known in the art.

[0397] In some embodiments of the present teachings, the biomarker detection reagents can be immobilized on a solid matrix, such as a porous strip, to form at least one biomarker detection site. In some embodiments, the measurement or detection area of ​​the porous strip can include multiple sites containing nucleic acids. In some embodiments, the test strip can also include sites for negative and / or positive controls. Alternatively, the control sites can be located on a strip separate from the test strip. In some cases, the different detection sites can contain different amounts of immobilized nucleic acid, e.g., a higher amount in the first detection site and a lower amount in subsequent sites. Upon addition of the test sample, the number of sites displaying a detectable signal quantitatively indicates the amount of biomarker present in the sample. The detection sites can be configured in any shape that is suitably detectable, for example, in the shape of a bar or dot spanning the width of the test strip.

[0398] In other embodiments of the present teachings, the kit can include a nucleic acid substrate array comprising one or more nucleic acid sequences. The nucleic acids on the array specifically identify one or more nucleic acid sequences represented by the MBDA markers. In various embodiments, the expression of one or more sequences represented by the MBDA markers can be identified by the effect of binding to the array. In some embodiments, the substrate array can be on a solid substrate, such as what is known as a "chip." See, for example, U.S. Patent No. 5,744,305. In some embodiments, the substrate array can be a solution array, such as xMAP (Luminex, Austin, TX), Cyvera (Illumina, San Diego, CA), RayBio Antibody Arrays (RayBiotech, Inc., Norcross, GA), CellCard (Vitra Bioscience, Mountain View, CA) and Quantum Dots' Mosaic (Invitrogen, Carlsbad, CA).

[0399] The machine-readable storage medium can include, for example, a data storage material encoded with machine-readable data or data arrays. The data and the machine-readable storage medium can be used for various purposes when using a machine programmed with instructions to use the data. Such purposes include, but are not limited to, storing, accessing and manipulating information regarding a subject's or population's risk over time, or risk in response to treatment, or drug discovery for inflammatory disease, and the like. The data, including the measurements of the biomarkers of the present teachings and / or the assessment of CVD risk from these biomarkers, can be implemented into a computer program running on a programmable computer, including a processor, a data storage system, one or more input devices, one or more output devices, and the like. The program code can be applied to the input data to perform the functions described herein and generate output information. This output information can then be applied to one or more output devices according to methods well known in the art. The computer can be, for example, a personal computer, a microcomputer, or a workstation of conventional design.

[0400] The computer programs can be implemented in a high-level procedural or object-oriented programming language to communicate with a computer system. The programs can also be implemented in a machine language or assembly language. The programming language may be a compiled or interpreted language. Each computer program can be stored in a storage medium or device such as a ROM, a magnetic diskette, and can be read by a programmable computer to configure and operate the computer when the storage medium or device is read by the computer to execute the procedures described. Any health-related data management system of the present teachings can be considered to be implemented as a computer-readable storage medium configured with a computer program, which causes the computer to operate in a specific manner to perform various functions as described herein.

[0401] The biomarkers disclosed herein can be used to generate a "subject biomarker profile" taken from a subject with an inflammatory disease. The subject biomarker profile can then be compared to a reference biomarker profile to diagnose or identify subjects at high CVD risk. The reference and subject biomarker profiles of the embodiments of the present teachings can be included in a machine-readable medium, such as an analog tape, particularly one that can be read by a CD-ROM or USB flash medium. Such machine-readable media can also include additional test results, such as measurements of clinical parameters and clinical evaluations. The machine-readable media can also include subject information, such as subject or family medical history. The machine-readable media can also include information regarding other disease activity algorithms and calculated scores or indices, as described herein.

[0402] The practice of the present teachings may employ methods of protein chemistry, biochemistry, recombinant DNA technology, and pharmacology, see, for example, T. Creighton, Proteins: Structures and Molecular Properties, 1993, W. Freeman and Co.; A. Lehninger, Biochemistry, Worth Publishers, Inc. (current supplement); J. Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edition, 1989; Methods In Enzymology, S. Colowick and N. Kaplan, eds., Academic Press, Inc.; Remington's Pharmaceutical Sciences, 18th Edition, 1990, Mack Publishing Company, Easton, PA; Carey and Sundberg, Advanced Organic Chemistry, Vols. A and B, 3rd Edition, 1993, Mack Publishing Company, Easton, PA; Edition, 1992, Plenum Press.

[0403] The practice of the present teachings can employ methods of biostatistical analysis. For example, J. Little and D. Rubin, Statistical Analysis with Missing Data, 2nd Edition 2002, John Wiley and Sons, Inc., NJ; M. Pepe, The Statistical Evaluation of Medical Tests for Classification and Prediction (Oxford Statistical Science Series) 2003, Oxford University Press, Oxford, UK; X. Zhoue et al., Statistical Methods in Diagnostic Medicine 2002, John Wiley and Sons,Inc.,NJ;T.Hastie et.al,The Elements of Statistical Learning:Data Mining,Inference,and Prediction,Second Edition 2009,Springer,NY;W.Cooley and P.Lohnes,Multivariate procedures for the behavioral science 1962,John Wiley and Sons,Inc.NY;E.Jackson,A User's Guide to Principal Components 2003,John Wiley and Sons, Inc., NY.

[0404] All publications, patents and literature specifically mentioned herein are hereby incorporated by reference in their entirety for all purposes.

[0405] Words specifically defined herein have the meaning given in the context of this disclosure as a whole and as typically understood by one of ordinary skill in the art. As used herein, the singular forms "a," "an," and "the" include plural.

[0406] While the present disclosure has been described in connection with various embodiments, it is not intended that the disclosure be limited to such embodiments, but rather, the present disclosure encompasses various alternatives, modifications, and equivalents, as will be appreciated by those skilled in the art.

[0407] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs.Methods and materials similar or equivalent to those described herein can be used to carry out or test the present invention, but suitable methods and materials are described below.In addition, the materials, methods, and examples in this specification are only illustrative and are not intended to be limiting.

[0408] Although the foregoing disclosure has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be understood by those skilled in the art that various changes and modifications may be practiced within the scope of the invention and the appended claims. EXAMPLES

[0409] Example 1: VECTRA Biomarker Cardiovascular Disease Score in Patients with Rheumatoid Arthritis A retrospective RA cohort was created using a 100% sample of fee-for-service Medicare data 2011-2016 of individuals undergoing testing with a commercially available MBDA test between 2001 and 2016. Data were linked to MBDA test code and MBDA test date defined by patient date of birth, sex, and procedure code (Current Procedural Terminology codes 81479, 83520, 84999, 86140, and 81490 submitted by Crescendo Biosciences or Myriad Genetics), and the treating rheumatologist's National Provider Identification number (NPI). Data were deterministically linked using previously published methods. The UAB Institutional Review Board approved the study.

[0410] Eligible Participants Eligible patients were: 1) Age 40 or older; 2) having at least one RA diagnosis code from a rheumatologist (ICD9 714.0; ICD10 M05.*, M06.* (excluding M06.4 and M06.1)); 3) receiving RA-specific treatment (e.g., biologics, tumor necrosis factor inhibitors, abatacept, rituximab, IL-6R, Janus kinase inhibitors, conventional synthetic disease-modifying antirheumatic drugs, e.g., methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine) prescribed at any time up to (including) the date of the first MBDA study; and 4) At least one relevant MBDA laboratory test was required.

[0411] Participants were also required to have continuous coverage under Medicare Part A (hospitalization coverage), Part B (outpatient care coverage), and Part D (prescription drug coverage) for at least 365 days.

[0412] The accuracy of this claims-based algorithm for identifying RA was over 85% and was further improved by collaboration with the MBDA test, given that the MBDA test was only approved for use in patients known to have RA (i.e., it was not a screening test to aid in the diagnosis of RA).

[0413] Baseline was fixed at the date of the first MBDA exam and included all available prior Medicare data; a minimum of 1 year was required. Patients with diagnostic codes for malignancy (other than nonmelanoma skin cancer), previous MI, or stroke during the baseline period were excluded. Follow-up could begin on the date of the first MBDA exam after all eligibility requirements were met. Follow-up ended with the earliest of CVD outcomes, occurrence of malignancy, nonfatal CVD events (initially treated as competing risks and later removed as they had minimal impact on outcomes), or end of study (12 / 31 / 2016).

[0414] CVD outcomes Composite CVD outcomes included hospitalized myocardial infarction (MI), stroke, and fatal CVD. MI was defined as ICD-9 diagnosis code 410.x1 or ICD-10 diagnosis code I21.* (any one digit given, * means any digit or letter) from an inpatient hospital stay that lasted at least one night in the hospital or if the patient died. Stroke was identified from hospital discharge using ICD-9 diagnosis codes 430.*, 431.*, 433.x1, 434.x1, 436.* or ICD-10 diagnosis codes I60.*, I61.*, I63.*, or I67.89. The positive predictive value for MI using this approach is approximately 93% or higher and for stroke is approximately 80–85% (18–20). Fatal CVD was identified using published algorithms with PPV ≥ 80%.

[0415] MBDA Biomarker Score The VECTRA MBDA trial was a panel of 12 protein biomarkers previously and repeatedly validated against DAS28-CRP in multiple RA cohorts consisting of seropositive and seronegative patients treated with various RA therapies. The biomarkers included in the MBDA reflect the biology of RA and consist of cytokines (IL-6, TNFRI), acute phase reactants (serum amyloid A, C-reactive protein), growth factors (VCAM-1, EGF, VEGF-A), matrix metalloproteinases (MMP-1, MMP-3), and adipokines (resistin, leptin). The 12 biomarkers were weighted with a published algorithm developed and validated based on correlation between the MBDA score and DAS28-CRP. Prior to and independent of this study, algorithms were developed to adjust the MBDA score for the effects of age, sex, and leptin (as a surrogate for adiposity). Similar to the original MBDA score, this adjusted MBDA score had a scale of 1 to 100, as well as RA disease activity categories of low (<30), moderate (30-44), and high (>44). This adjustment has been used routinely since December 2017. For use in this study, MBDA scores were converted to adjusted MBDA scores. As used herein, the term "MBDA score" refers to adjusted MBDA scores. All MBDA scores were ordered by specialists as part of routine care and performed at a commercial laboratory.

[0416] Individual MBDA test results were disregarded if they were out within 14 days of discharge. Given that IL-6R treatment may affect the MBDA score in a way that may confound CVD risk prediction, MBDA test results were also disregarded if patients had used sarilumab or tocilizumab in the past 90 days.

[0417] In addition to both the MBDA score and its 12 log-transformed component biomarkers, various demographic and clinical predictors were also considered for inclusion in the predictive model based on their association with expected CVD risk informed by subject matter expertise and the medical literature. Candidate predictors could include age, sex, race, diabetes diagnosis and medication, hypertension, hyperlipidemia, tobacco use, history of cardiovascular disease other than MI or stroke [e.g., angina or acute coronary syndrome without MI, atrial fibrillation, peripheral vascular disease], use of RA medications listed above, glucocorticoids, and nonsteroidal anti-inflammatory drugs. All candidate predictors except for the biomarkers were obtained using Medicare data. Laboratory results other than the MBDA test results and its component biomarkers were not available in the Medicare data.

[0418] Based on a pre-specified analysis plan, we performed a principled approach to model building and selection following the Explicit Reporting of Multivariate Predictive Models for Individual Prognosis or Diagnosis (TRIPOD) guidelines. First, the cohort was randomly split 2:1 into separate training and testing (i.e., internal validation) datasets. All feature selection and model building was performed on the training dataset only.

[0419] All candidate features were then characterized descriptively. Predictors considered for model building included established CVD risk factors, diagnostic codes, demographic and biomarker variables. Means (SD) were calculated for continuous predictors and percentages for categorical predictors, and patients were stratified according to whether they had had a CVD event or not.

[0420] In constructing the statistical model that is part of the method of the present invention, the patient risk of CVD was estimated as a function of predictors using Cox proportional hazards regression on the training data only. Individual biomarker concentrations were natural log transformed. To account for possible nonlinearities, a squared term of age was included as a candidate predictor. MBDA scores were hyperbolic tangent transformed, and the parameters of the hyperbolic tangent transformation were selected based on maximum likelihood estimation and updated at each step of model construction. Consistent with one of the options described in the TRIPOD guidance, the model was constructed using a elimination method. In the first step, all candidate predictors were included. In each subsequent step, the least significant variable (highest p-value) was removed and the model was refitted with the remaining variables. This was done until the p-values ​​of all remaining variables were below the threshold of 0.05.

[0421] A total of five prediction methods were compared using the training dataset. These five methods were: 1) Age + Gender; 2) age + sex + CRP; 3) parsimonious clinical model (age + sex + tobacco use + diabetes + hypertension + history of other CVD conditions); 4) the parsimonious clinical model (number 3 above) plus CRP; and 5) Final VECTRA-CVD score MBDA-based method.

[0422] Considerations in selecting the final VECTRA-CVD score method were based on model discrimination, calibration, parsimony, and the expected feasibility of collecting covariates required in routine clinical care settings.

[0423] In this large cohort of over 30,000 RA patients, a biomarker-based CVD prediction model was derived and validated for use in RA patients. In addition to reflecting the contribution of systemic inflammation as measured by MBDA, the method incorporated four clinical predictors that should be readily available to clinicians at the point of care. The model was shown to be accurate both in the group of patients used to derive it, and across various important patient subgroups, as well as in the randomly split samples used for internal validation. The goal of such a risk assessment tool was to reflect the important contribution of active RA to elevated CVD risk and provide rheumatologists and their patients with a useful tool at the point of care to facilitate collaborative decision-making. These discussions could encompass topics including ways to mitigate the contribution of RA disease activity, as well as highlight traditional CV risk factors that may need to be addressed with patients.

[0424] The validated CVD risk prediction score and method of the present invention can provide clinicians with an easy-to-use scale for assessing CVD risk at point-of-care.The method is based on several easily available traditional CVD risk factors combined with age and RA-related disease activity based on serum biomarkers.The method of the present invention emphasizes actionable risk CVD factors, RA-related disease activity, and tobacco use and obesity (e.g., as represented by leptin biomarker), but also includes other traditional CVD risk factors such as hypertension and diabetes.

[0425] Example 2: Risk categorization of VECTRA biomarker cardiovascular disease scores in patients with rheumatoid arthritis. VECTRA biomarker CVD 3-year risk % determination for patients with rheumatoid arthritis Patients in the training dataset were grouped into three risk groups by their predicted risk of CVD at 3 years. The 3-year estimated risk was calculated as 100 × (1-Aexp[B × VECTRA-CVD score]), where A reflects the baseline risk, i.e. the probability of not having a CVD event within 3 years with all covariates set to 0, and B is a calibration constant applied to the test dataset (see below). The 3-year time window was chosen based on data availability. For the purpose of categorizing risk values, 3-year cut points corresponding to 10-year ACC / AHA thresholds of 5% (+-0.1%), 7.5% (+-0.1%) and 20% (+-0.1%) risk were obtained by bootstrapping. Briefly, age and sex models were estimated in a cohort of RA patients for which 10-year data were available (2006–2016), but for which relevant biomarker information was not available as it preceded the availability of the MBDA trial, which was first available in 2010. The cut points selected for categorization were low (0–<1.3%), borderline risk (cumulative risk ≥1.3%–<1.8%), intermediate risk (≥1.8–<5.2%), and high risk (≥5.2%).

[0426] For example, the VECTRA-CVD score can be calculated according to Formula IX: TIFF2024161429000016.tif69128

[0427] Biostatistical tools were used to calculate the 3-year % risk of CVD in RA patients based on the VECTRA biomarker set and VECTRA-CVD score obtained using clinical data.

[0428] Patients were grouped into three risk groups according to their predicted risk of CVD at 3 years. The 3-year risk estimate % was calculated according to formula X: TIFF2024161429000017.tif15128 where A reflects the baseline risk, which is the probability of not having a CVD event within 3 years with all covariates set to 0, and B is a calibration constant applied to the study clinical data.

[0429] Testing and internal validation The risk scores from the training data of the above five methods were compared in terms of their 3-year c-index (discrimination), calibration, and goodness of fit (observed versus expected at 3 years in predicted risk decile categories), the incremental contribution of the MBDA-based CVD risk score method, and the Net Reclassification Index (NRI). The purpose of the NRI table was to assess whether the more complex methods meaningfully changed the way individual patients were classified in terms of risk categories (low, intermediate, high, etc.). In addition, survival curves were generated for each of the three predicted risk groups.

[0430] SAS 9.4 was used for data preparation, and R version 2.4 and the R packages survival, nricens and pec were used for assessing model performance, calculating NRI and C-indices and generating plots.

[0431] Sensitivity analysis Various sensitivity analyses were performed to ensure that the performance of the final method was consistent across important subgroups of patients. These included patients under 65 years of age, under 75 years of age, with and without diabetes, with and without taking statins, and with and without a history of CVD-related symptoms. Sensitivity analyses were also performed on patients censored at the time of addition or switch to biologics to address the possibility that RA disease activity measured by biomarkers may be significantly misclassified over time.

[0432] Example 3: Favorable performance of VECTRA-CVD scoring for patients with rheumatoid arthritis Cohort Selection After applying the inclusion and exclusion criteria, a total of 30,751 RA patients were eligible for the cohort. Baseline characteristics were as follows: mean age 69 years, 23% of patients were <65 years, 18% were male; 8% were black. Prevalence of various CVD-related comorbidities was high, including diabetes (40%) and hypertension (79%), as well as statin use (42%). Approximately 60% of patients were taking methotrexate, 33% were taking TNF inhibitors (TNFi), and 15% were receiving non-TNFi biologics. Median CRP level was 1.5 mg / L, and median MBDA score was 41, interpreted as the upper limit of moderate RA disease activity. Median (IQR) follow-up time after index date was 1.7 (1.3, 2.7) years. Distribution of baseline candidate predictors in the RA cohort, including comorbidities, using 12-month baseline and all available prior data, is shown in Table 7.

[0433] Table 7. Distribution of baseline candidate predictors in the RA cohort TIFF2024161429000018.tif26128TIFF2024161429000019.tif25590†Natural logarithm transformation *ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker

[0434] Training an MBDA-based model Only age and sex parameters were significant, as were various expected comorbidities including diabetes, hypertension, history of other CVD events, and smoking. However, in the final MBDA-based model, VECTRA-CVD score, male gender, and CRP were surprisingly no longer significant, and the final CVD risk score equation was 1.6076×tanh(VECTRA / 33.0807)−0.1711×ln(leptin)+0.5724×ln(TNFRI)+0.1454×ln(MMP3)+0.0314×age+0.2691×smoking+0.2732×diabetes+0.2694×hypertension+0.3378×history of CVD, where leptin, TNFR1, and MMP3 refer to the serum concentrations of the respective biomarkers in ng / ml.

[0435] Figure 1 shows the relationship between predicted VECTRA CVD score (x-axis) and CVD 3-year risk% (y-axis) in RA patients. In Figure 1, the proportion of patients falling into low+borderline, intermediate, and high CVD 3-year risk% categories was 15.1%, 54.3%, and 30.6%, respectively.

[0436] Figure 2 shows the distribution of patients for the relationships in Figure 1. The distribution in Figure 2 indicates that for all levels of predicted VECTRA-CVD score, patients were found with a wide range of CVD 3-year risk %. This distribution and relationship indicates that the score is predictively valid and meaningful for patients with a wide range of risk levels.

[0437] Figure 3 shows the correlation between predicted CVD risk scoring (x-axis) and CVD risk patient outcomes (y-axis). The goodness of fit of the final CVD 3-year risk % across deciles of the internal validation dataset is shown in Figure 3. As shown in Figure 3, the calibration of the final model was good across deciles, and the goodness-of-fit test statistic indicated a reasonable fit (p=0.13). The actual observed risk was within the confidence limits of the predicted risk for almost all decile groups. Overall, the median (IQR) of the predicted CVD 3-year risk % was 3.4%. The goodness of fit of the data points to the dashed line indicates that a very strong correlation exists between CVD 3-year risk % and patient outcomes.

[0438] Comparison and evaluation on internal validation datasets The c-index (AUROC) for predicting CVD risk at 3 years increased across models and as covariates were added: 0.66 for the age + sex model, 0.67 for age, sex, and CRP, 0.69 for the parsimonious clinical model without CRP, 0.70 for the parsimonious clinical model including CRP, and 0.72 for the final CVD 3-year risk% method. Notably, predictions based on the final CVD 3-year risk% method showed surprisingly little variability and discriminated surprisingly well among patients than the traditional method using only age and sex.

[0439] The CVD 3-year risk% method advantageously accounted for the contribution of RA-associated inflammation to CVD risk by including VECTRA score as a covariate. Figure 4 shows the relationship between inflammation and CVD risk. In Figure 4, the results of the CVD 3-year risk% method in the internal validation dataset are plotted according to VECTRA score. A positive association was observed between increasing VECTRA score and predicted CVD risk. At all levels of VECTRA score, a wide range of CVD risk values ​​was observed, consistent with the different contributions of other covariates in the cohort.

[0440] Survival Rate Chart Plots of CVD event-free survival were used to demonstrate favorable separation of low-, intermediate-, and high-risk categories over time using VECTRA-CVD score and the final CVD 3-year risk % method.

[0441] Figure 5 shows the results of the method for clinically validating the predictive ability of the CVD 3-year risk % value of the present invention. Figure 5 shows the CVD event-free survival rate of RA subjects. The plotted lines show the survival rates corresponding to the low, medium, and high CVD risk group thresholds of the predicted CVD 3-year risk % value of the present invention (n=10,275).

[0442] Figure 6 shows the results of the method for clinically validating the predictive ability of the CVD 3-year risk % value of the present invention. Figure 6 shows the CVD event-free survival rate of RA subjects. The plotted lines show the survival rates corresponding to the low / borderline, intermediate, and high CVD risk group thresholds of the predicted CVD 3-year risk % value of the present invention (n=10,275).

[0443] Figure 7 shows the results of the method for clinically validating the predictive ability of the CVD 3-year risk % value of the present invention. Figure 7 shows the CVD event-free survival rate of RA subjects. The plotted lines show the survival rates corresponding to the low, borderline, intermediate, and high CVD risk group thresholds of the predicted CVD 3-year risk % value of the present invention (n=10,275).

[0444] Example 4: Performance of VECTRA-CVD Score Determination for Rheumatoid Arthritis Patients Compared to Conventional Methods The performance of the VECTRA-CVD score and CVD 3-year risk % methods were compared with conventional methods for determining CVD risk in patients with rheumatoid arthritis.

[0445] Figure 8 shows the unexpectedly superior accuracy of the method of the present invention in assessing CVD 3-year risk percentages in RA subjects. The bar graph in Figure 8 shows that the method of the present invention based on the VECTRA-CVD score ("MBDA-based") was surprisingly much more accurate than various methods that did not include the VECTRA-CVD score. This can be seen by the incremental increase in the likelihood ratio test (LRT) (y-axis, height of the shaded area) from left to right in Figure 8.

[0446] In Figure 8, the left bar shows that the determination of CVD risk based on the clinical parameters age + sex only (first model) contributed incrementally to the VECTRA-CVD score (second model) when entered into the calculation first.

[0447] Similarly, the second, third and fourth bars from the left also show that the determination of CVD risk based only on the parameters age + sex + CRP (biomarker), the set of clinical parameters not including CRP, and the set of clinical parameters including CRP, respectively, contributed incrementally to the VECTRA CVD score (second model) when first entered into the calculation. The sets of clinical parameters were age, sex, diabetes, hypertension, smoking, and history of CVD.

[0448] Importantly, in Figure 8, the right-hand bar shows that the VECTRA-CVD score method (first model) makes the incremental contribution of other methods (second model, small shaded areas at the top of the bar) negligible when entered into the calculation first. This is statistical evidence of the fact that the VECTRA-CVD score method disclosed herein unexpectedly exhibits superior accuracy to conventional methods for assessing CVD 3-year risk percentage values ​​in RA subjects.

[0449] In summary, FIG. 8 shows that by bivariate analysis, use of the VECTRA-CVD score of the present invention achieved a very high level of accuracy over conventional methods in determining CVD 3-year % risk in RA subjects.

[0450] Similarly, Figure 9 shows the unexpectedly superior accuracy of the method of the present invention in assessing CVD 3-year risk percentages in RA subjects. The bar graph in Figure 9 shows that the method of the present invention based on VECTRA-CVD score ("MBDA-based") was surprisingly much more accurate than various methods that do not include VECTRA score. This can be seen by the incremental increase in likelihood ratio test (LRT) (y-axis, height of shaded area) from left to right in Figure 9.

[0451] In FIG. 9, the left bar shows that the determination of CVD risk based only on the clinical parameters age+gender+CRP (first model) contributed incrementally to the VECTRA-CVD score (second model) when entered into the calculation first.

[0452] Similarly, the second and third bars from the left show that the CVD risk determination based only on the set of clinical parameters without CRP and the set of clinical parameters including CRP (first model), respectively, contributed incrementally to the VECTRA CVD score (second model) when first entered into the calculation. The sets of clinical parameters were age, sex, diabetes, hypertension, smoking, and history of CVD.

[0453] Importantly, in Figure 9, the right-hand bar shows that the VECTRA-CVD score method (first model) makes the incremental contribution of other methods (second model, small shaded area at the top of the bar) negligible when entered into the calculation first. This is statistical evidence of the fact that the VECTRA-CVD score method disclosed herein unexpectedly showed superior accuracy to conventional methods for assessing CVD 3-year risk percentage values ​​in RA subjects.

[0454] In summary, FIG. 9 shows that by bivariate analysis, use of the VECTRA-CVD score of the present invention achieved a very high level of accuracy over conventional methods in determining CVD 3-year % risk in RA subjects.

[0455] Furthermore, the results of sensitivity analyses showed that findings were consistent across all important subgroups of interest, including patients younger than 65 years, patients younger than 75 years, patients with and without diabetes, patients taking and not taking statins, and patients with and without a history of CVD, whether or not patients added or switched biologics.

[0456] Example 5: Comparison of the performance of VECTRA-CVD score and CVD 3-year risk % determination to conventional methods for patients with rheumatoid arthritis by bivariate analysis Bivariate analysis of the performance of the final VECTRA-CVD score method compared with conventional methods for determining CVD risk in patients with rheumatoid arthritis is shown in Table 8.

[0457] Table 8. Bivariate analysis of final VECTRA-CVD score method performance TIFF2024161429000020.tif121169

[0458] The method of the present invention surprisingly accurately assessed the CVD 3-year risk % of RA subjects using VECTRA-CVD score values ​​compared to conventional non-VECTRA methods.

[0459] Table 8 shows the unexpectedly superior accuracy of the method of the present invention for assessing CVD 3-year % risk in RA subjects using VECTRA-CVD score values ​​compared to conventional non-VECTRA methods.

[0460] Table 8 shows that by bivariate analysis, the method of the present invention based on the VECTRA-CVD score ("MBDA-based") was surprisingly much more accurate than the various methods that did not include the VECTRA-CVD score.

[0461] For example, Table 8 shows that the p-values ​​for the conventional non-VECTRA methods were very large, ranging from 0.084 to 0.526, by bivariate analysis. This means that the conventional non-VECTRA methods and their corresponding sets of variables essentially add very little to the results obtained by the VECTRA-CVD score. The p-values ​​for the VECTRA-CVD score are approximately 10 -9 ~10 -20 , which represents a much higher accuracy of the method using the VECTRA-CVD score and corresponding variables, e.g., the VECTRA biomarkers.

[0462] In summary, Table 8 demonstrates that bivariate analyses demonstrate that the traditional set of variables (e.g., age + sex, age + sex + CRP) is not responsible for the unexpectedly superior accuracy of the VECTRA-CVD score.

[0463] In summary, Table 8 shows that by bivariate analysis, use of the VECTRA-CVD score of the present invention achieved a surprisingly high level of accuracy over conventional methods in determining CVD 3-year % risk in RA subjects.

[0464] Example 6: Comparison of the performance of VECTRA-CVD score and CVD 3-year risk % determination to conventional methods for patients with rheumatoid arthritis by reclassification analysis. Validation of CVD risk categories in RA patients using multi-biomarker disease activity and clinical variables The net reclassification table can show that the method of the invention accurately assesses the risk of CVD in RA, thus expanding the population of patients included in the treatment.

[0465] The large number of patients reclassified in Tables 9-20 below indicates that the methods of the present invention for accurately assessing the risk of CVD in RA can expand the population of patients included in the treatment.

[0466] The large number of patients reclassified in Tables 9-20 below indicates that reclassification of patient risk in the methods of the present invention that accurately assess the risk of CVD in RA may alter the type of CVD or RA treatment applied to a patient population.

[0467] In Tables 9-20 below, the "Observed" percentages are the cumulative incidence of observed CVD events.

[0468] In Tables 9-20 below, over one third, as much as 75%, of the patients were reclassified by the final CVD 3-year risk % method of the present invention. This data shows the surprisingly improved accuracy of the CVD 3-year risk % method of the present invention. The CVD 3-year risk % method of the present invention can favorably reclassify a significant proportion of patients into higher categories of predicted CVD risk, thereby improving the treatment, prognosis, and monitoring of CVD-RA patients.

[0469] Table 9 shows that compared to the age+gender only method, the % final CVD 3-year risk method of the present invention reclassified a significant proportion of patients into higher categories of predicted CVD risk.

[0470] Table 9. Reclassification of patients based on CVD 3-year risk % of the present invention and CVD risk of RA compared to age + sex method TIFF2024161429000021.tif97160

[0471] Table 10 shows that compared to the age+gender+CRP method, the final CVD 3-year risk % method of the present invention reclassified a significant proportion of patients into different categories of predicted CVD risk. Three categories were used: low / borderline, intermediate, and high.

[0472] Table 10. Reclassification of patients based on CVD 3-year risk % of the present invention and CVD risk of RA compared to use of the age+gender+CRP method TIFF2024161429000022.tif98160

[0473] Table 11 shows that compared to clinical variable methods not including CRP, the final CVD 3-year risk % method of the present invention reclassified a significant proportion of patients into different categories of predicted CVD risk. Three categories were used: low / borderline, intermediate, and high.

[0474] Table 11. Reclassification of patients based on CVD risk in RA compared to the method using CVD 3-year risk % of the present invention and clinical variables not including CRP TIFF2024161429000023.tif111160*Clinical variables were age, sex, diabetes, hypertension, smoking, and history of CVD.

[0475] Table 12 shows that compared to clinical variable methods including CRP, the final CVD 3-year risk % method of the present invention reclassified a significant proportion of patients into different categories of predicted CVD risk. Three categories were used: low / borderline, intermediate, and high.

[0476] Table 12. Reclassification of patients based on CVD risk in RA compared to the method using CVD 3-year risk % of the present invention and clinical variables including CRP TIFF2024161429000024.tif110160*Clinical variables were age, sex, diabetes, hypertension, smoking, and history of CVD.

[0477] Table 13 shows that compared to the age+gender method, the final CVD 3-year risk % method of the present invention reclassified a significant proportion of patients into different categories of predicted CVD risk. Three categories were used: low, medium, and high.

[0478] Table 13. Reclassification of patients based on CVD 3-year risk % of the present invention and CVD risk of RA compared to using the age + sex method TIFF2024161429000025.tif110160

[0479] Table 14 shows that compared to the age+gender+CRP method, the final CVD 3-year risk % method of the present invention reclassified a significant proportion of patients into different categories of predicted CVD risk. Three categories were used: low, medium, and high.

[0480] Table 14. Reclassification of patients based on CVD 3-year risk % of the present invention and CVD risk of RA compared to using the age+gender+CRP method TIFF2024161429000026.tif103160

[0481] Table 15 shows that compared to clinical variable methods that did not include CRP, the final CVD 3-year risk % method of the present invention reclassified a significant proportion of patients into different categories of predicted CVD risk. Three categories were used: low, medium, and high.

[0482] Table 15. Reclassification of patients based on CVD risk in RA compared to the method using CVD 3-year risk % of the present invention and clinical variables not including CRP TIFF2024161429000027.tif110160*Clinical variables were age, sex, diabetes, hypertension, smoking, and history of CVD.

[0483] Table 16 shows that the final CVD 3-year risk % method of the present invention reclassified a significant proportion of patients into different categories of predicted CVD risk compared to the clinical variable method including CRP. Three categories were used: low, medium, and high.

[0484] Table 16. Reclassification of patients based on CVD risk in RA compared to the use of CVD 3-year risk % of the present invention and clinical variables including CRP TIFF2024161429000028.tif110160*Clinical variables were age, sex, diabetes, hypertension, smoking, and history of CVD.

[0485] Table 17 shows that compared to the age+gender method, the final CVD 3-year risk % method of the present invention reclassified a significant proportion of patients into different categories of predicted CVD risk. Four categories were used: low, borderline, intermediate, and high.

[0486] Table 17. Reclassification of patients based on CVD risk in RA compared to the use of the CVD 3-year risk % of the present invention and age + sex variables TIFF2024161429000029.tif133167

[0487] Table 18 shows that compared to the age+gender+CRP method, the final CVD 3-year risk % method of the present invention reclassified a significant proportion of patients into different categories of predicted CVD risk. Four categories were used: low, borderline, intermediate, and high.

[0488] Table 18. Reclassification of patients based on CVD 3-year risk % of the present invention and CVD risk of RA compared to using the age+gender+CRP method TIFF2024161429000030.tif133167

[0489] Table 19 shows that compared to clinical variable methods not including CRP, the final CVD 3-year risk % method of the present invention reclassified a significant proportion of patients into different categories of predicted CVD risk. Four categories were used: low, borderline, intermediate, and high.

[0490] Table 19. Reclassification of patients based on CVD risk in RA compared to the method using CVD 3-year risk % of the present invention and clinical variables not including CRP TIFF2024161429000031.tif133167*Clinical variables were age, sex, diabetes, hypertension, smoking, and history of CVD.

[0491] Table 20 shows that compared to clinical variable methods including CRP, the final CVD 3-year risk % method of the present invention reclassified a significant proportion of patients into different categories of predicted CVD risk. Four categories were used: low, borderline, intermediate, and high.

[0492] Table 20. Reclassification of patients based on CVD risk in RA compared to the use of CVD 3-year risk % of the present invention and clinical variables including CRP TIFF2024161429000032.tif133167*Clinical variables were age, sex, diabetes, hypertension, smoking, and history of CVD.

[0493] Example 7: Comparison of the performance of VECTRA-CVD score and CVD 3-year risk % determination to conventional methods for patients with rheumatoid arthritis by hazard ratio analysis. Validation of CVD risk categories in RA patients using multi-biomarker disease activity and clinical variables Hazard ratios for the various methods can be shown that the methods of the invention accurately assess the risk of CVD in RA, thus expanding the population of patients included in the treatment.

[0494] To mitigate the elevated CVD risk in RA, appropriate risk stratification may be required to identify high-risk patients as targets for intervention.The method of the present invention can advantageously be made available to clinicians in real time at the most actionable point of care.In particular, in RA patients, the method of the present invention can take into account the impact of disease and its characteristics (including disease activity and systemic inflammation) to fully characterize the entire CVD risk present in RA.The method of the present invention thus expands the population for risk prediction and accurately determines the CVD risk of RA patients.

[0495] An accurate method for predicting the risk of CVD events in RA patients that reflects the magnitude of RA disease activity and associated systemic inflammation can make CVD risk stratification more accurate and accessible.Therefore, the method of the present invention can treat RA patients for CVD prevention care who would otherwise not be treated by conventional methods.

[0496] Systemic inflammation has been assessed by one or more biomarkers that reflect RA disease activity. The Multi-Biomarker Disease Activity (MBDA) score can be used, which is highly correlated with RA disease activity measured by the Disease Activity Score in 28 Joints (DAS28). In both cross-sectional and longitudinal studies, the MBDA score tracked RA disease activity.

[0497] The biomarker clinical method of the present invention can be implemented at point-of-care for RA. In the present disclosure, a RA-specific CVD prediction score, the VECTRA-CVD score, is provided, which uses RA-related biomarkers in conjunction with clinical variable data to predict CVD risk. Clinical data can be obtained by clinicians using clinical findings that are readily available, or can be extracted from electronic systems (e.g., electronic health records, or health insurance claims data used for population health management). The method of the present invention can provide prognosis, as well as preventive CVD care in RA, and includes the component of RA-related systemic inflammation that contributes to excess CVD risk in RA.

[0498] Hazard ratios of the different methods compared to the method of the present invention are shown in Table 21. Hazard ratios of the different methods for CVD risk were obtained using training data (n=20,476).

[0499] Table 21: Comparative analysis of hazard ratios using the CVD 3-year risk% method of the present invention TIFF2024161429000033.tif159164CRP: C-reactive protein;CVD: cardiovascular disease;MMP3;TNFRI †Serum concentrations (ug / mL for CRP, ng / mL for leptin, MMP3 and TNFR1), natural log transformed ‡ Hyperbolic tangent transformation (tanh(a*adjusted VECTRA score:a:1 / 33.08073)

[0500] Example 8: Comparison of performance of VECTRA-CVD score methods References from TRIPOD One procedure can be to apply automated variable selection methods in multivariate modeling. Several variants are available in modern software, including forward selection, elimination, and combinations of both. Elimination starts with a full model including all potential predictors. Variables are sequentially removed from the model until a prespecified stopping rule (such as P-value or Akaike Information Criterion [AIC]) is met. Forward selection starts with an empty model, and predictors are sequentially added until a prespecified stopping rule is met.

[0501] When automated predictor selection procedures are used, elimination of variables may generally be preferred since all correlations between predictors are taken into account in the modeling procedure. The use of automated predictor selection strategies during multivariate modeling may result in overfitted and optimistic models, especially when sample sizes are small. However, the degree of overfitting due to the use of predictor selection strategies can be estimated and taken into account in so-called internal validation procedures.

[0502] The TRIPOD statement suggests consideration of automated predictor selection procedures (variable elimination may be preferred) or shrinkage methods such as LASSO for multivariate model building, and caution to account for overfitting. It may be undesirable to penalize coefficients of known strong predictors (such as age in CVD), as lasso does. Furthermore, subset selection procedures can provide better predictive accuracy than lasso in situations with high signal-to-noise ratios (i.e., poor features). It may be clinically practical to have a model that is as parsimonious as possible. For these reasons, we used variable elimination with a significance level of 0.05 as the inclusion criterion for variable selection.

[0503] One issue in these automated predictor selection procedures can be the criteria for predictors selected for inclusion in the model. The predictor significance level (α) is sometimes set at 0.05, as is common in hypothesis testing. However, simulation studies show that higher values ​​should be considered, especially in small datasets. In such cases, the use of AIC for selection can be an attractive option. This accounts for model fit while penalizing the number of parameters estimated, and corresponds to using α = 0.157.

[0504] Example 9: Comparison of methods for CVD risk in RA patients using the Multi-Biomarker Disease Activity (MBDA) test combined with clinical factors of the VECTRA-CVD score method This example demonstrates multiple models for predicting CVD risk using a surrogate multi-biomarker disease activity score (MBDA) combined with clinical factors in rheumatoid arthritis (RA) patients.

[0505] The analysis was to develop and validate a method for cardiovascular disease risk in patients with rheumatoid arthritis. A separate method was also developed for a set of subpopulations of RA patients (e.g., stratified by age 65 years or older and younger than 65 years old). A CVD risk prediction algorithm was developed and validated using MBDA-related Medicare data. MBDA data was linked to Medicare by patient's date of birth, sex, NPI and MBDA test date. MBDA test date in Medicare was identified by specific and non-specific Current Procedural Terminology (CPT) codes. Patient eligibility criteria were described in Example 1 above.

[0506] Main outcomes / dependent variables: The primary outcome was time to a composite CVD event, including any myocardial infarction (MI), stroke, or fatal CVD. Fatal CVD was identified by a claims-based algorithm described in Xie et al., Pharmacoepidemiology and drug safety (2018) 27:740-750.

[0507] Predictor or stratification variables (see below): Variables considered potential predictors of CVD included age, sex, the 12 MBDA biomarkers and various MBDA scores, race, physician-diagnosed diabetes, hyperlipidemia, hypertension, obesity, smoking, chronic kidney disease; prescription of statins, other lipid-lowering medications, antihypertensive medications (ARBs, ACEIs, CCBs, beta-blockers), glucocorticoid use, RA medications including MTX, other csDMARDs, NSAIDs and biologics.

[0508] Statistical Considerations: Cox regression was used for model building. Lasso is used for initial variable selection. Additional variable selection is based on variable hazard ratios, partial likelihood ratio test statistics and p-values, as well as practical considerations for inclusion in commercial test request forms.

[0509] See also Curtis JR, Xie F, Chen L, et al., Biomarker-related risk for myocardial infarction and serious infections in patients with rheumatoid arthritis: a population-based study, Annals of the Rheumatic Diseases 2018; Vol. 77, pp. 386-392, which is incorporated by reference in its entirety.

[0510] Definition of CVD events: Composite CVD includes MI, stroke and fatal CVD. These are defined as follows: MI: one or more hospital diagnosis codes (410.x1) from inpatient hospital diagnosis codes in any location (primary or secondary location); also requiring at least one night of hospitalization unless the patient dies; Stroke: one or more hospital diagnosis codes for hemorrhagic or ischemic stroke from inpatient discharge (primary or secondary location) (430.*, 431.*, 433.x1, 434.x1, 436.*, I60.xx, I61.xx, I63.xx, I67.89); Fatal CVD: Fatal CVD is identified using a claims-based algorithm with PPV >= 0.80 (Xie et al., Pharmacoepidemiology and drug safety (2018) 27: 740-750).

[0511] Endpoint / Outcome Assessment: Time to composite CVD event was calculated as the difference between the date of first eligible MBDA exam and the date of hospitalization for MI or stroke or death from fatal CVD. For patients who did not experience a composite CVD event during follow-up, the time to composite CVD event was censored as the difference between the date of first eligible MBDA exam and the date of last follow-up.

[0512] Results: Below we report the results of 16 alternative methods for determining CVD risk in RA patients from Example 1. The methods used different subsets of the data, and the variables for each model were selected using a elimination method starting with MBDA (or adjusted MBDA), MBDA squared (or adjusted MBDA squared), individual MBDA biomarkers, age, age squared, and sex; and a diagnosis of hypertension, hyperlipidemia, or diabetes.

[0513] In each case where sex was a variable, "M" means "male" and the reported hazard ratios reflect CVD risk in men compared with women. In some methods, patients with hypertension and / or taking statin medications were excluded from the analysis, but this does not necessarily exclude them from use of the method.

[0514] For each method, the components or variables of the method are the “parameters” listed in the corresponding table, the coefficients of each variable are referred to as “parameter estimates,” and the statistical significance (i.e., p-value) of each variable is referred to as “Pr>ChiSq.”

[0515] Exemplary ROCs are shown in FIGS.

[0516] CVD Risk Methods Using MBDA and Squared MBDA in Patients 40 Years and Older: (Table 22) CVD risk model TIFF2024161429000034.tif53128

[0517] (Table 23) Estimated values TIFF2024161429000035.tif55166

[0518] Table 24. Summary of elimination method TIFF2024161429000036.tif80140

[0519] CVD Risk Methods Using MBDA and Squared MBDA in Patients Aged 40-75 Years: Table 25: CVD risk model TIFF2024161429000037.tif64128

[0520] (Table 26) Estimated values TIFF2024161429000038.tif74160

[0521] Table 27. Summary of elimination method TIFF2024161429000039.tif69129

[0522] CVD risk methods using adjusted MBDA and squared adjusted MBDA in patients aged 40 years and older: Table 28: Type 3 test TIFF2024161429000040.tif54128

[0523] Table 29. Analysis of maximum likelihood estimates TIFF2024161429000041.tif69166

[0524] Table 30. Summary of elimination method TIFF2024161429000042.tif79132

[0525] CVD risk methods using adjusted MBDA and squared adjusted MBDA in patients aged 40-75 years: Table 31 Type 3 test TIFF2024161429000043.tif64134

[0526] Table 32. Analysis of maximum likelihood estimates TIFF2024161429000044.tif79169

[0527] Table 33. Summary of elimination method TIFF2024161429000045.tif69144

[0528] CVD risk methods using MBDA in patients aged 40 years and older, excluding patients with hypertension from the analysis: Table 34: Type 3 test TIFF2024161429000046.tif60128

[0529] Table 35. Analysis of maximum likelihood estimates TIFF2024161429000047.tif79161

[0530] (Table 36) TIFF2024161429000048.tif83132

[0531] CVD risk methods using MBDA in patients aged 40 years and older, excluding patients taking statin medications from the analysis: Table 37 Type 3 test TIFF2024161429000049.tif60128

[0532] Table 38. Analysis of maximum likelihood estimates TIFF2024161429000050.tif74161

[0533] Table 39. Summary of elimination method TIFF2024161429000051.tif89132

[0534] CVD risk methods using MBDA in patients aged 40 years and older, excluding patients with hypertension or taking statin medications from the analysis: (Table 40) Type 3 test TIFF2024161429000052.tif78128

[0535] Table 41. Analysis of maximum likelihood estimates TIFF2024161429000053.tif98163

[0536] Table 42. Summary of elimination method TIFF2024161429000054.tif65136

[0537] CVD risk methods using MBDA in patients aged 40-75 years, excluding patients with hypertension from the analysis: Table 43: Type 3 test TIFF2024161429000055.tif59128

[0538] Table 44. Analysis of maximum likelihood estimates TIFF2024161429000056.tif73161

[0539] Table 45. Summary of elimination method TIFF2024161429000057.tif89128

[0540] CVD risk using MBDA in patients aged 40-75 years, excluding patients taking statins from the analysis: Table 46: Type 3 test TIFF2024161429000058.tif59128

[0541] Table 47. Analysis of maximum likelihood estimates TIFF2024161429000059.tif68163

[0542] Table 48: Summary of elimination method TIFF2024161429000060.tif95134

[0543] CVD risk using MBDA in patients aged 40-75 years, excluding patients with hypertension or taking statin medications from the analysis: Table 49: Type 3 test TIFF2024161429000061.tif42128

[0544] Table 50. Analysis of maximum likelihood estimates TIFF2024161429000062.tif56161

[0545] Table 51. Summary of elimination method TIFF2024161429000063.tif101129

[0546] CVD risk using adjusted MBDA in patients aged 40 years and older, excluding patients with hypertension from the analysis: Table 52 Type 3 test TIFF2024161429000064.tif60128

[0547] Table 53. Analysis of maximum likelihood estimates TIFF2024161429000065.tif76170

[0548] Table 54. Summary of elimination method TIFF2024161429000066.tif83128

[0549] CVD risk using adjusted MBDA in patients aged 40 years and older, excluding patients taking statins from the analysis: Table 55: Type 3 test TIFF2024161429000067.tif65128

[0550] Table 56. Analysis of maximum likelihood estimates TIFF2024161429000068.tif76170

[0551] Table 57. Summary of elimination method TIFF2024161429000069.tif89128

[0552] CVD risk methods using adjusted MBDA in patients aged 40 years and older, excluding patients with hypertension or taking statin medications from the analysis: Table 58: Type 3 test TIFF2024161429000070.tif84128

[0553] Table 59: Analysis of maximum likelihood estimates TIFF2024161429000071.tif100170

[0554] (Table 60) Summary of elimination method TIFF2024161429000072.tif59128

[0555] CVD risk methods using adjusted MBDA in patients aged 40-75 years, excluding patients with hypertension from the analysis: (Table 61) Type 3 test TIFF2024161429000073.tif59128

[0556] Table 62: Analysis of maximum likelihood estimates TIFF2024161429000074.tif71170

[0557] Table 63. Summary of elimination method TIFF2024161429000075.tif89136

[0558] CVD risk using adjusted MBDA in patients aged 40-75 years, excluding patients taking statins from the analysis: (Table 64) Type 3 test TIFF2024161429000076.tif59128

[0559] Table 65: Analysis of maximum likelihood estimates TIFF2024161429000077.tif66170

[0560] Table 66: Summary of elimination method TIFF2024161429000078.tif95131

[0561] CVD risk using adjusted MBDA in patients aged 40-75 years, excluding patients with hypertension or taking statin medication from the analysis: (Table 67) Type 3 test TIFF2024161429000079.tif42128

[0562] Table 68: Analysis of maximum likelihood estimates TIFF2024161429000080.tif54170

[0563] (Table 69) Summary of elimination method TIFF2024161429000081.tif101139

[0564] CVD risk model including age, sex, and CRP in patients aged 40-75 years: (Table 70) Type 3 test TIFF2024161429000082.tif30128

[0565] Table 71: Analysis of maximum likelihood estimates TIFF2024161429000083.tif44158

[0566] CVD risk model including age, sex, and CRP in patients aged 40 years and older: (Table 72) Type 3 test TIFF2024161429000084.tif30128

[0567] Table 73: Analysis of maximum likelihood estimates TIFF2024161429000085.tif44158

Claims

1. 1. A method for assessing the risk of cardiovascular disease (CVD) in a subject with an inflammatory disease, comprising the steps of: measuring in a sample from the subject protein levels of three or more biomarkers from a set of biomarkers including leptin (LEP), tumor necrosis factor receptor superfamily, member 1A (TNFR1), matrix metallopeptidase 3 (stromelysin 1, progelatinase) (MMP3), C-reactive protein, pentraxin related (CRP), interleukin 6 (interferon, beta 2) (IL6), serum amyloid A1 (SAA1), chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1), epidermal growth factor (beta-urogastron) (EGF), vascular cell adhesion molecule 1 (VCAM1), matrix metallopeptidase 1 (interstitial collagenase) (MMP1), resistin (RETN), and vascular endothelial growth factor A (VEGFA); and Calculating a CVD risk score for the subject using an interpretation function using the protein levels, one or more clinical conditions, and a set of training clinical data of a reference group, wherein the three or more biomarkers include LEP, TNFR1, and MMP3.

2. validating said CVD risk score using an interpretation function using said protein levels, one or more clinical conditions, and a set of validation clinical data for a reference group.

2. The method of claim 1, further comprising:

3. The method of claim 1, wherein the sample is a blood sample.

4. 2. The method of claim 1, wherein the subject is over 40 years of age.

5. 10. The method of claim 1, wherein the subject has no history of heart attack or stroke.

6. 2. The method of claim 1, wherein the inflammatory disease is rheumatoid arthritis (RA).

7. 2. The method of claim 1, wherein said clinical conditions include age, sex, smoking, diabetes, hypertension, and history of cardiovascular disease.

8. 2. The method of claim 1, wherein the clinical conditions include age, sex, smoking, diabetes, hypertension, history of cardiovascular disease, gender, obesity, body mass index, race, and ethnicity.

9. 2. The method of claim 1, wherein the reference group is patients tested for rheumatoid arthritis (RA) and / or cardiovascular disease (CVD) activity.

10. 2. The method of claim 1, wherein the reference group is Medicare patients.

11. 2. The method of claim 1, wherein the three or more biomarkers include LEP, TNFR1, MMP3, CRP, IL6, and SAA1.

12. 2. The method of claim 1, wherein the three or more biomarkers include LEP, TNFR1, MMP3, CRP, IL6, SAA1, CHI3L1, EGF, VCAM1, MMP1, RETN, and VEGFA.

13. 2. The method of claim 1, wherein the CVD risk score is validated using clinical data selected from DAS score, DAS28 score, DAS28-CRP score, DAS28-ESR score, Sharp score, tender joint count score (TJC), and swollen joint count score (SJC).

14. 2. The method of claim 1, wherein the step of calculating the CVD risk score comprises calculating an adjusted MBDA score and calculating the CVD risk score by combining the adjusted MBDA score with clinical conditions using an interpretation function.

15. The interpretation function may be: survival regression analysis, Cox proportional hazards, Box-Cox transformation, clustering machine learning, hierarchical clustering analysis, centroid clustering, distributional clustering, density clustering, cluster data mining, analysis of variance (ANOVA), AdaBoosting, classification and regression trees (CART), boosted CART, random forests (RF), recursive partitioning trees (RPART), Curds and Whey (CW), Curds and Whey-Lasso, principal component analysis (PCA), factor rotation analysis, linear discriminant analysis (LDA), Eigengene linear discriminant analysis (ELDA), quadratic discriminant analysis, discriminant function analysis (DFA), hidden Markov models, kernel density estimation, kernel partial least squares algorithm, kernel matching pursuit algorithm, kernel Fisher discriminant analysis algorithm, kernel principal component analysis algorithm; linear regression, stepwise regression, incremental stepwise regression, Lasso shrinkage selection method, Elastic Net regularization and selection, Lasso and Elastic 13. The method of claim 1, wherein the classification algorithms include one or more of: .Net regularized generalized linear model, logistic regression (LogReg), K-nearest neighbors (KNN), nonlinear regression, classification, neural networks, partial least squares, rule-based classification, shrunken centroids (SC), sliced ​​inverse regression, Standard for the Exchange of Product model data, Application Interpreted Constructs (StepAIC), super principal component (SPC) regression, support vector machine (SVM), and recursive support vector machine (RSVM), and combinations thereof.

16. 2. The method of claim 1, wherein the interpretation function provides an algorithm comprising a hyperbolic tangent or an exponential function of the biomarker score.

17. The method of claim 1 , wherein the protein level is measured by immunoassay.

18. The method of any one of claims 1 to 17, further comprising the step of recommending treatment for CVD to the subject based on a CVD risk score above a threshold level, or recommending no treatment for CVD based on a CVD risk score below a threshold level.

19. 20. The method of claim 18, wherein the treatment is one of the following: the treatment being administered to the subject at the time the sample was obtained; cessation of treatment being administered to the subject at the time the sample was obtained; Tapering of the treatment being administered to the subject at the time the sample was obtained.

20. 20. The method of claim 18, wherein the treatment is one or more of administering a drug, performing surgery, performing rehabilitation, administering treatment for another disease or condition in the subject, and ameliorating the subject's symptoms.

21. 20. The method of claim 18, wherein the treatment is administering one or more agents selected from cholesterol-lowering agents, blood flow-increasing agents, cardiac rhythm regulators, cardiac rhythm stabilizers, agents that reduce blood blockage, beta-blockers, ACE inhibitors, aldosterone inhibitors, angiotensin II receptor blockers, calcium channel blockers, cholesterol-lowering agents, diuretics, inotropes, electrolyte supplements, PCSK9 inhibitors, and vasodilators.

22. 19. The method of claim 18, wherein the treatment is administering a DMARD selected from MTX, azathioprine (AZA), bucillamine (BUC), chloroquine (CQ), cyclosporine, doxycycline (DOXY), hydroxychloroquine (HCQ), intramuscular gold (IM gold), leflunomide (LEF), levofloxacin (LEV), sulfasalazine (SSZ), folinic acid, D-pencilamine, gold auranofin, gold aurothioglucose, gold thiomalate, cyclophosphamide, chlorambucil, infliximab, adalimumab, etanercept, golimumab, anakinra, abatacept, rituximab, and tocilizumab.

23. 20. The method of claim 18, wherein the treatment is one or more of percutaneous coronary intervention, coronary artery bypass surgery, heart valve repair or replacement surgery, bariatric surgery, cardiac rehabilitation, therapeutic physical programs, dietary modification or restriction, smoking cessation, diabetes treatment, hypertension treatment, symptom relief, reducing the risk of recurrence, reducing the severity of recurrence, reducing heart failure or heart attack, and reducing stroke.

24. Identifying a subject who has an inflammatory disease and is at risk for cardiovascular disease (CVD) and would benefit from treatment for CVD based on a CVD risk score that exceeds a threshold level. The method of any one of claims 1 to 17, further comprising:

25. 25. The method of claim 24, wherein the threshold level is one of a borderline risk threshold, a moderate risk threshold, and a high risk threshold based on a CVD 3-year risk or a CVD 10-year risk.

26. 2. A method for treating cardiovascular disease (CVD) in a subject having an inflammatory disease and in need of treatment for CVD, comprising the steps of: measuring in a sample from the subject protein levels of three or more biomarkers from a set of biomarkers including leptin (LEP), tumor necrosis factor receptor superfamily, member 1A (TNFR1), matrix metallopeptidase 3 (stromelysin 1, progelatinase) (MMP3), C-reactive protein, pentraxin related (CRP), interleukin 6 (interferon, beta 2) (IL6), serum amyloid A1 (SAA1), chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1), epidermal growth factor (beta-urogastron) (EGF), vascular cell adhesion molecule 1 (VCAM1), matrix metallopeptidase 1 (interstitial collagenase) (MMP1), resistin (RETN), and vascular endothelial growth factor A (VEGFA); calculating a CVD risk score for the subject using an interpretation function using the protein levels, one or more clinical conditions, and a set of training clinical data of a reference group, wherein the three or more biomarkers comprise LEP, TNFR1, and MMP3; identifying a subject having an inflammatory disease and at risk for cardiovascular disease (CVD) based on a CVD risk score above a threshold level; and administering to the subject a treatment for CVD or RA.

27. validating said CVD risk score using an interpretation function using said protein levels, one or more clinical conditions, and a set of validation clinical data for a reference group.

27. The method of claim 26, further comprising:

28. 27. The method of claim 26, wherein the sample is a blood sample.

29. 27. The method of claim 26, wherein the subject is over 40 years of age.

30. 27. The method of claim 26, wherein the subject has no history of heart attack or stroke.

31. 27. The method of claim 26, wherein the inflammatory disease is rheumatoid arthritis (RA).

32. 27. The method of claim 26, wherein the clinical conditions include age, sex, smoking, diabetes, hypertension, and history of cardiovascular disease.

33. 27. The method of claim 26, wherein the clinical conditions include age, sex, smoking, diabetes, hypertension, history of cardiovascular disease, gender, obesity, body mass index, race, and ethnicity.

34. 27. The method of claim 26, wherein the reference group is patients tested for rheumatoid arthritis (RA) and / or cardiovascular disease (CVD) activity.

35. 27. The method of claim 26, wherein the reference group is Medicare patients.

36. 27. The method of claim 26, wherein the three or more biomarkers comprise LEP, TNFR1, MMP3, CRP, IL6, and SAA1.

37. 27. The method of claim 26, wherein the three or more biomarkers include LEP, TNFR1, MMP3, CRP, IL6, SAA1, CHI3L1, EGF, VCAM1, MMP1, RETN, and VEGFA.

38. 27. The method of claim 26, wherein the CVD risk score is validated using clinical data selected from DAS score, DAS28 score, DAS28-CRP score, DAS28-ESR score, Sharp score, tender joint count score (TJC), and swollen joint count score (SJC).

39. 27. The method of claim 26, wherein the step of calculating a CVD risk score comprises calculating an adjusted MBDA score and calculating the CVD risk score by combining the adjusted MBDA score with clinical conditions.

40. The interpretation function may be: survival regression analysis, Cox proportional hazards, Box-Cox transformation, clustering machine learning, hierarchical clustering analysis, centroid clustering, distributional clustering, density clustering, cluster data mining, analysis of variance (ANOVA), AdaBoosting, classification and regression trees (CART), boosted CART, random forests (RF), recursive partitioning trees (RPART), curds and whey (CW), curds and whey-Lasso, principal component analysis (PCA), factor rotation analysis, linear discriminant analysis (LDA), Eigengene linear discriminant analysis (ELDA), quadratic discriminant analysis, discriminant function analysis (DFA), hidden Markov models, kernel density estimation, kernel partial least squares algorithm, kernel matching pursuit algorithm, kernel Fisher discriminant analysis algorithm, kernel principal component analysis algorithm; linear regression, stepwise regression, incremental stepwise regression, Lasso shrinkage selection method, Elastic Net regularization and selection, Lasso and Elastic 27. The method of claim 26, wherein the method comprises one or more of the following: .Net regularized generalized linear model, logistic regression (LogReg), K nearest neighbors (KNN), nonlinear regression, classification, neural networks, partial least squares, rule-based classification, shrink centroids (SC), stratified inverse regression, product model data exchange standard application adaptation construct (StepAIC), super principal component (SPC) regression, support vector machine (SVM), and recursive support vector machine (RSVM), and combinations thereof.

41. 27. The method of claim 26, wherein the treatment is one or more of administering a drug, performing surgery, performing rehabilitation, administering treatment for another disease or condition in the subject, and ameliorating the subject's symptoms.

42. 27. The method of claim 26, wherein the treatment is administration of one or more agents selected from cholesterol-lowering agents, blood flow-increasing agents, cardiac rhythm regulators, cardiac rhythm stabilizers, agents that reduce blood blockage, beta-blockers, ACE inhibitors, aldosterone inhibitors, angiotensin II receptor blockers, calcium channel blockers, cholesterol-lowering agents, diuretics, inotropes, electrolyte supplements, PCSK9 inhibitors, and vasodilators.

43. 27. The method of claim 26, wherein the treatment is administering a DMARD selected from MTX, azathioprine (AZA), bucillamine (BUC), chloroquine (CQ), cyclosporine, doxycycline (DOXY), hydroxychloroquine (HCQ), intramuscular gold (IM gold), leflunomide (LEF), levofloxacin (LEV), sulfasalazine (SSZ), folinic acid, D-pencilamine, gold auranofin, gold aurothioglucose, gold thiomalate, cyclophosphamide, chlorambucil, infliximab, adalimumab, etanercept, golimumab, anakinra, abatacept, rituximab, and tocilizumab.

44. 27. The method of claim 26, wherein the treatment is one or more of percutaneous coronary intervention, coronary artery bypass surgery, heart valve repair or replacement surgery, bariatric surgery, cardiac rehabilitation, therapeutic physical programs, dietary modification or restriction, smoking cessation, diabetes treatment, hypertension treatment, symptom relief, reducing the risk of recurrence, reducing the severity of recurrence, reducing heart failure or heart attack, and reducing stroke.

45. Identifying a subject who has an inflammatory disease and is at risk for cardiovascular disease (CVD) and would benefit from treatment for CVD based on a CVD risk score that exceeds a threshold level. The method of any one of claims 26 to 44, further comprising:

46. 46. ​​The method of claim 45, wherein the threshold level is one of a borderline risk threshold, a moderate risk threshold, and a high risk threshold based on a CVD 3-year risk or a CVD 10-year risk.

47. monitoring the response of a subject with an inflammatory disease, the subject being at risk for having CVD, to treatment by obtaining one or more additional CVD risk scores for the subject. The method of any one of claims 26 to 44, further comprising:

48. A method for prognosing a subject having an inflammatory disease and at risk of having CVD, comprising the steps of: measuring in a blood sample from the subject protein levels of three or more biomarkers from a set of biomarkers including leptin (LEP), tumor necrosis factor receptor superfamily, member 1A (TNFR1), matrix metallopeptidase 3 (stromelysin 1, progelatinase) (MMP3), C-reactive protein, pentraxin related (CRP), interleukin 6 (interferon, beta 2) (IL6), serum amyloid A1 (SAA1), chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1), epidermal growth factor (beta-urogastron) (EGF), vascular cell adhesion molecule 1 (VCAM1), matrix metallopeptidase 1 (interstitial collagenase) (MMP1), resistin (RETN), and vascular endothelial growth factor A (VEGFA); calculating a CVD risk score for the subject from the protein levels of the biomarkers and one or more clinical conditions using an interpretation function, wherein the three or more biomarkers include LEP, TNFR1, and MMP3; and prognosing the subject as having a poor prognosis for CVD based on a CVD risk score exceeding a threshold level.

49. 49. The method of claim 48, wherein the threshold level is one of a borderline risk threshold, a moderate risk threshold, and a high risk threshold based on a CVD 3-year risk or a CVD 10-year risk.

50. A kit for assessing risk of cardiovascular disease (CVD) in a subject with an inflammatory disease, comprising: reagents for measuring protein levels of three or more biomarkers from a set of biomarkers including leptin (LEP), tumor necrosis factor receptor superfamily, member 1A (TNFR1), matrix metallopeptidase 3 (stromelysin 1, progelatinase) (MMP3), C-reactive protein, pentraxin related (CRP), interleukin 6 (interferon, beta 2) (IL6), serum amyloid A1 (SAA1), chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1), epidermal growth factor (beta-urogastron) (EGF), vascular cell adhesion molecule 1 (VCAM1), matrix metallopeptidase 1 (interstitial collagenase) (MMP1), resistin (RETN), and vascular endothelial growth factor A (VEGFA) in a blood sample from the subject; and Instructions for using said reagent to obtain said biomarker level.

51. 1. A system for assessing risk of cardiovascular disease (CVD) in a subject with an inflammatory disease, comprising: a processor for receiving the subject's protein levels measured in a blood sample for three or more biomarkers from a set of biomarkers including leptin (LEP), tumor necrosis factor receptor superfamily, member 1A (TNFR1), matrix metallopeptidase 3 (stromelysin 1, progelatinase) (MMP3), C-reactive protein, pentraxin related (CRP), interleukin 6 (interferon, beta 2) (IL6), serum amyloid A1 (SAA1), chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1), epidermal growth factor (beta-urogastron) (EGF), vascular cell adhesion molecule 1 (VCAM1), matrix metallopeptidase 1 (interstitial collagenase) (MMP1), resistin (RETN), and vascular endothelial growth factor A (VEGFA); The process is as follows: calculating a CVD risk score for the subject from the protein levels of the biomarkers and one or more clinical conditions using an interpretation function, wherein the three or more biomarkers comprise LEP, TNFR1, and MMP3; Identifying a subject who has an inflammatory disease and is at risk for cardiovascular disease (CVD) based on a CVD risk score above a threshold level. one or more processors for executing A display for displaying and / or reporting said CVD risk score. Including, the system.

52. 52. The method of claim 51, wherein the threshold level is one of a borderline risk threshold, a moderate risk threshold, and a high risk threshold based on a CVD 3-year risk or a CVD 10-year risk.

53. 1. A non-transitory machine-readable storage medium having stored therein instructions for execution by a processor, the instructions causing the processor to perform steps of a method for assessing a risk of cardiovascular disease (CVD) in a subject having an inflammatory disease, the method comprising the steps of: receiving measured protein levels from a blood sample from the subject for three or more biomarkers from a set of biomarkers including leptin (LEP), tumor necrosis factor receptor superfamily, member 1A (TNFR1), matrix metallopeptidase 3 (stromelysin 1, progelatinase) (MMP3), C-reactive protein, pentraxin related (CRP), interleukin 6 (interferon, beta 2) (IL6), serum amyloid A1 (SAA1), chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1), epidermal growth factor (beta-urogastron) (EGF), vascular cell adhesion molecule 1 (VCAM1), matrix metallopeptidase 1 (interstitial collagenase) (MMP1), resistin (RETN), and vascular endothelial growth factor A (VEGFA); calculating a CVD risk score for the subject from the protein levels of the biomarkers and one or more clinical conditions using an interpretation function, wherein the three or more biomarkers comprise LEP, TNFR1, and MMP3; identifying a subject having an inflammatory disease and at risk for cardiovascular disease (CVD) based on a CVD risk score above a threshold level; and transmitting said CVD risk score to a processor output for display and / or reporting.

54. 54. The method of claim 53, wherein the threshold level is one of a borderline risk threshold, a moderate risk threshold, and a high risk threshold based on a CVD 3-year risk or a CVD 10-year risk.

Citation Information

Patent Citations

  • Biomarkers and methods for measuring and monitoring inflammatory disease activity

    US9200324B2